The Central Role of CPT1A in Systemic Treatment of Multiple Sclerosis and Comorbidities; a Pathway to a New Cure by Mørkholt, Anne Skøttrup
 
  
 
Aalborg Universitet
The Central Role of CPT1A in Systemic Treatment of Multiple Sclerosis and
Comorbidities; a Pathway to a New Cure
Mørkholt, Anne Skøttrup
DOI (link to publication from Publisher):
10.5278/vbn.phd.med.00124
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Mørkholt, A. S. (2019). The Central Role of CPT1A in Systemic Treatment of Multiple Sclerosis and
Comorbidities; a Pathway to a New Cure. Aalborg Universitetsforlag. Aalborg Universitet. Det
Sundhedsvidenskabelige Fakultet. Ph.D.-Serien https://doi.org/10.5278/vbn.phd.med.00124
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 24, 2020
A
n
n
e Sk
ø
ttr
u
p M
ø
r
k
h
o
lt
th
e C
en
tr
A
l r
o
le o
F C
pt1A In
 SYSteM
IC
 tr
eAtM
en
t o
F M
u
ltIple
SC
ler
o
SIS A
n
D
 C
o
M
o
r
B
ID
ItIeS; A pAth
W
AY to
 A n
eW
 C
u
r
e
the CentrAl role oF Cpt1A In
SYSteMIC treAtMent oF MultIple
SCleroSIS AnD CoMorBIDItIeS; 
A pAthWAY to A neW Cure
BY
Anne Skøttrup Mørkholt
Dissertation submitteD 2019
 
 
THE CENTRAL ROLE OF CPT1A IN 
SYSTEMIC TREATMENT OF MULTIPLE 
SCLEROSIS AND COMORBIDITIES; A 
PATHWAY TO A NEW CURE 
PHD DISSERTATION 
by 
Anne Skøttrup Mørkholt 
 
Dissertation submitted 15th February 2019 
 
. 
  
Dissertation submitted: 15th February 2019
PhD supervisor:  Associate Prof. John Dirk Vestergaard Nieland,
   Aalborg University
PhD committee:  Clinical Associate Professor Claudia Christine Hilt Pfleger
   Aalborg University Hospital
   Associate Professor Simon Glerup Pedersen
   Aarhus University
   Professor Jon Daniël Laman
   University Medical Center Groningen
PhD Series: Faculty of Medicine, Aalborg University
Department: Department of Health Science and Technology 
ISSN (online): 2246-1302
ISBN (online): 978-87-7210-396-9
Published by:
Aalborg University Press
Langagervej 2
DK – 9220 Aalborg Ø
Phone: +45 99407140
aauf@forlag.aau.dk
forlag.aau.dk
© Copyright: Anne Skøttrup Mørkholt
Printed in Denmark by Rosendahls, 2019
CV 
Anne Skøttrup Mørkholt 
Born in 1991, Brønderslev, Denmark 
 
Education 
2013-2015 M.Sc. in Medicine with Industrial Specialization, Biomedicine, 
 Aalborg University 
2010-2013 B.Sc. in Medicine with Industrial Specialization, Aalborg 
 University 
 
Positions 
2018-2019 Research assistant, Department of Health Science and Technology, 
 Aalborg University 
2015-2018 PhD student, Department of Health Science and Technology, 
 Aalborg University 
2015-2015 Research assistant, Department of Health Science and Technology, 
 Aalborg University 
2013-2015 Student assistant at Medical School of Health, Aalborg University 
 
Publications 
Mørkholt AS, Trabjerg MS, Oklinski MKE, Bolther L, Kroese LJ, Pritchard CEJ, 
Huijbers IJ, Nieland JDV. CPT1A plays a key role in the development and treatment 
of multiple sclerosis and experimental autoimmune encephalomyelitis. [Manuscript 
submitted].  
Trabjerg MS, Andersen DC, Mørk K, Skjønnemand MLN, Oklinski MK, Mørkholt 
AS, Kroese LJ, Pritchard CEJ, Huijbers IJ, Nielsen S, Nieland JD. Blocking 
carnitine palmitoyl transferase 1 is highly efficacious in the treatment of Parkinson´s 
disease: A new way to a cure? [Manuscript submitted]. 
Mørkholt AS, Oklinski MK, Larsen A, Bockermann R, Issazadeh-Navikas S, 
Nieland JGK, Kwon TH, Corthals A, Nielsen S, Nieland JD. Pharmacological 
inhibition of carnitine palmitoyl transferase 1 inhibits and reverses experimental 
autoimmune encephalomyelitis in rodents. [Manuscript submitted].  
Mørkholt AS*, Kastaniegaard K*, Trabjerg MS, Gopalasingam G, Niganze W, 
Larsen A, Stensballe A, Nielsen S, Nieland JD. Identification of brain antigens 
recognized by autoantibodies in experimental autoimmune encephalomyelitis-
induced animals treated with etomoxir or interferon-β. Sci Rep. 2018 May 4; 8(1). 
Mørkholt AS, Wiborg O, Nieland JGK, Nielsen S, Nieland JD. Blocking of 
carnitine palmitoyl transferase 1 potently reduces stress-induced depression in rat 
highlighting a pivotal role of lipid metabolism. Sci Rep. 2017 May 19; 7(1). 
* = Equal contribution 
 
Conference presentations 
Mørkholt AS. The role of dysregulated lipid metabolism in an EAE model of mice 
mimicking the Inuit CPT1A mutation. Consortium of Multiple Sclerosis Centers 
(CMSC), 02 June 2018, Nashville, Tennessee, USA. 
Mørkholt AS. Looking at multiple sclerosis as a systemic disease; comparing the 
effect of the lipid metabolism blocker, etomoxir, with the inflammatory blocker, 
interferon-β. Consortium of Multiple Sclerosis Centers (CMSC), 25 May 2017, New 
Orleans, Louisiana, USA. 
Mørkholt AS. Blocking the lipid metabolism as a new treatment strategy for 
multiple sclerosis. Consortium of Multiple Sclerosis Centers (CMSC), 02 June 2016, 
National Harbor, Maryland, USA. 
 
Conference abstracts 
Mørkholt AS, Trabjerg MS, Huijbers IJ, Pritchard CEJ, Kroese LJ, Nieland JD. 
Identifying the role of lipid metabolism in an experimental autoimmune 
encephalomyelitis mice model. Consortium of Multiple Sclerosis Centers (CMSC), 
May 30-June 02 2018, Nashville, Tennessee, USA.  
Trabjerg MS, Mørkholt AS, Nielsen S, Nieland JDN. Identifying the role of lipid 
metabolism in central nervous systems diseases; is there a common theme for MS, 
ALS, Parkinson´s disease and depression? Consortium of Multiple Sclerosis Centers 
(CMSC), May 30-June 02 2018, Nashville, Tennessee, USA.  
Mørkholt AS, Kastaniegaard K, Trabjerg MS, Niganze W, Gopalasingam G, Larsen 
A, Stensballe A, Nielsen S, Nieland JD. Comparison of etomoxir, a lipid metabolism 
blocker, and interferon-β treatment on antibody recognition of brain proteins in 
multiple sclerosis. Consortium of Multiple Sclerosis Centers (CMSC), 24-27 May 
2017, New Orleans, Louisiana, USA. 
Mørkholt AS*, Kastaniegaard K*, Stensballe A, Nielsen S, Nieland JD. 
Characterization of human autoantibody response to brain proteins in multiple 
sclerosis patients. Consortium of Multiple Sclerosis Centers (CMSC), 24-27 May 
2017, New Orleans, Louisiana, USA. 
Mørkholt AS, Larsen A, Wiborg O, Issazadeh-Navikas S, Nieland JGK, Nielsen S, 
Nieland JD. Highly effective treatment of multiple sclerosis by blocking lipid 
metabolism. 32nd Congress of the European Committee for Treatment and Research 
in Multiple Sclerosis (ECTRIMS), 14-17 September 2016, London.  
Mørkholt AS, Larsen A, Nieland JGK, Issazadeh-Navikas S, Nielsen S, Nieland 
JD. Blocking lipid metabolism as a new treatment strategy for multiple sclerosis. 
Consortium of Multiple Sclerosis Centers (CMSC), 01-04 June 2016, National 
Harbor, Maryland, USA. 
Nieland JD, Nieland JGK, Mørkholt AS, Larsen A, Corthals A, Issazadeh-Navikas 
S, Bolther L, Nielsen S. CPT1a mutation leads the way for new medication for the 
treatment of multiple sclerosis. 31st Congress of the European Committee for 
Treatment and Research in Multiple Sclerosis (ECTRIMS), 07-10 October 2015, 
Barcelona.  
Mørkholt AS*, Routhe LJ*, Moos T. The functional expression of ferroportin in 
primary rat neuronal culture. European Iron Club, 11-14 September 2014, Verona. 
* = Equal contribution

ENGLISH SUMMARY 
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune and 
neurodegenerative disease of the central nervous system (CNS). Pathological 
features include loss of oligodendrocytes, demyelination, axonal degeneration, 
inflammatory plaques and break down of the blood-brain barrier. Several 
mechanisms for the immunoreactivity affecting the immune system such as 
molecular mimicry, altered peptide ligand or bystander activation have been 
proposed. The treatment of MS today includes disease-modifying therapies, 
ameliorating the inflammatory response which is not able to prevent the progressive 
neurological decline contributing to disability. This incomplete traditional 
framework of the understanding of the etiology and pathology of MS and the 
common comorbid condition, depression, indicates that the pathological pathways 
of MS and comorbidities remain unexplored and undiscovered. 
A new systemic framework of the understanding of MS originates from dysfunction 
of the lipid metabolism. The brain energy homeostasis is maintained by a 
competing relationship between oxidation of glucose and fatty acids, depending on 
the energy demand of the tissue. Glucose is the primary energy substrate in the 
brain used in glycolysis and oxidation of glucose whereas fatty acids are used in β-
oxidation as an alternative energy substrate. In the fatty acid metabolism, a carnitine 
shuttle with carnitine palmitoyl transferase 1 (CPT1) is required as the outer 
mitochondrial membrane is impermeable to fatty-acyl CoA. Thereby, CPT1 serves 
as the regulatory rate-limiting step in β-oxidation of fatty acids.  
Several human mutations for CPT1A are identified and the mutations CPT1A 
P479L and CPT1A G710E are of particular interest since these are associated with 
low prevalences of MS and depression. Given that the lipid metabolism and thus 
CPT1 plays a pivotal role in the energy homeostasis, it is tempting to hypothesize 
that dysregulation of this may underlie diseases of the CNS. The aim of the PhD 
thesis is therefore to obtain a thorough understanding of the metabolism in health 
and disease in order to clarify the etiology and pathology of MS and depression, 
which are presented in Manuscript I-IV. 
To accomplish the aim of the PhD thesis, state-of-art in vivo animal models of MS 
(experimental autoimmune encephalomyelitis, EAE) and depression (chronic mild 
stress, CMS) were established. The efficacy of lipid metabolism blockage was 
evaluated, both pharmacological by using etomoxir targeting CPT1 and genetically 
by generating Cpt1a P479L mice.  
In Manuscript I, the efficacy of etomoxir was investigated in EAE-induced animals 
showing decreased clinical score, which indicates amelioration of the disease. 
Moreover, the efficacy of etomoxir was compared to interferon-β treatment where 
the efficacy of lipid metabolism blockage was superior to the standard treatment of 
MS targeting T cell function. In Manuscript II, the efficacy of etomoxir versus 
interferon-β on the B cell function was evaluated in EAE-induced animals by 
investigating the autoantibody response. A pallet of autoantigens was modulated 
after etomoxir treatment, showing that blockage of lipid metabolism causes 
alterations in the antibody response, thus targeting B cell function. In Manuscript 
III, the efficacy of the Cpt1a P479L mutation was evaluated in an EAE model, 
showing that Cpt1a P479L EAE mice were resistant to disease development 
compared to wild type EAE mice. Moreover, high-fat diet is thought to exacerbate 
the disease course however the Cpt1a P479L EAE mice were unaffected whilst 
wild type EAE mice were affected. In Manuscript IV, the efficacy of etomoxir was 
investigated in CMS-induced animals, which revealed reduced anhedonic behavior 
compared to the standard treatment escitalopram. Moreover, etomoxir reversed the 
depression-like phenotype in 90 % of the animals, compared to 57 % of the animals 
receiving escitalopram.  
In conclusion, the results presented in this PhD thesis provide knowledge 
supporting the new systemic framework for understanding the etiology and 
pathology of MS and depression. This indicates a change of paradigm towards 
development, progression and treatment of CNS diseases, in particular MS and 
depression, with lipid metabolism playing a central role opening up a pathway to a 
new cure.  
 
  
DANSK RESUME 
Multipel sklerose (MS) er en kronisk, inflammatorisk, autoimmun og 
neurodegenerativ sygdom i centralnervesystemet. De patologiske karaktertræk 
omfatter tab af oligodendrocytter, demyelinisering, nedbrydning af axoner, 
inflammatoriske plaks samt nedbrydning af blod-hjerne-barrieren. Der er foreslået 
mange forskellige mekanismer for immunreaktivitet herunder ’molecular mimicry’, 
’altered peptide ligand’ og ’bystander activation’. I dag omfatter behandlingen af 
MS sygdomsmodificerende terapier, der dæmper det inflammatoriske respons, dog 
er disse terapier ikke i stand til at forhindre det progressive neurologiske tab, der 
bidrager til funktionsnedsættelse. Dette ufuldstændige traditionelle perspektiv af 
forståelsen for ætiologi og patologi af MS og dets mest almindelige komorbiditet 
depression indikerer, at de patologiske pathways for MS og depression fortsat er 
uudforskede og uopdagede.  
Et nyt systemisk perspektiv af forståelsen for MS omhandler dysfunktionel 
fedtsyremetabolisme. Hjernens energihomeostase opretholdes ved et konkurrerende 
forhold mellem oxidation af glukose og fedtsyrer afhængig af energikravet i vævet. 
Glukose er det primære energisubstrat i hjernen og bruges i glykolysen og oxidation 
af glukose, hvorimod fedtsyrer anvendes i β-oxidation som en alternativ 
energikilde. I fedtsyremetabolismen er det nødvendigt med en carnitin transporter 
kaldet carnitin palmitoyl transferase 1 (CPT1), da den ydre mitokondrielle 
membran er impermeabel for fedt acyl-CoA. Dermed fungerer CPT1 som det 
regulerende hastighedsbestemmende trin i β-oxidation af fedtsyrer. 
Der er identificeret mange humane mutationer i CPT1A og mutationerne CPT1A 
P479L og CPT1A G710E er af særlig interesse, da de er associeret med lav 
prævalens for MS og depression. Givet at fedtsyremetabolismen og dermed CPT1 
spiller en afgørende rolle i energihomeostasen, er det oplagt at fremsætte en 
hypotese, der omfatter at dysregulering af denne ligger til grund for sygdomme i 
centralnervesystemet. Formålet med denne PhD afhandling er at opnå en grundig 
forståelse af metabolismen i raske og syge for at kunne afdække ætiologi og 
patologi af MS og depression, hvilket er præsenteret i Manuskript I-IV. 
For at opnå formålet med denne PhD afhandling, er in vivo dyremodeller for MS 
(eksperimentel autoimmun encephalomyelitis, EAE) og depression (kronisk mild 
stress, CMS) blevet etableret. Her blev virkningen af blokering af 
fedtsyremetabolismen både farmakologisk, ved brug af etomoxir målrettet CPT1, 
og genetisk, ved generering af Cpt1a P479L mus, undersøgt. 
I Manuskript I blev virkningen af etomoxir undersøgt i EAE-inducerede dyr, der 
viser nedsat klinisk score, som indikerer afdæmpning af sygdommen. Ydermere 
blev virkningen af etomoxir sammenlignet med interferon-β, hvor blokering af 
fedtsyremetabolismen var bedre i forhold til standardbehandlingen for MS, der er 
målrettet T celle funktion. I Manuskript II blev virkningen af etomoxir versus 
interferon-β evalueret på B celle funktion i EAE-inducerede dyr ved at undersøge 
autoantistofresponset. En vifte af autoantigener var ændret efter behandling med 
etomoxir, hvilket betyder, at blokering af fedtsyremetabolismen forårsager 
ændringer i antistofresponset og dermed er målrettet B celle funktion. I Manuskript 
III blev virkningen af Cpt1a P479L mutationen evalueret i en EAE model, der viste, 
at Cpt1a P479L EAE mus var resistente mod at udvikle sygdom sammenlignet med 
vildtype EAE mus. Derudover har det vist sig, at fedtrig kost forværrer 
sygdomsforløbet, men her var Cpt1a P479L EAE musene upåvirkede, hvorimod 
vildtype EAE musene var påvirkede. I Manuscript IV blev virkningen af etomoxir 
undersøgt i CMS-inducerede dyr, hvor denne behandling viste reduceret anhedonisk 
adfærd sammenlignet med standardbehandlingen escitalopram. Ydermere var 
etomoxir i stand til at omvende den depressionslignende fænotype i 90 % af dyrene 
i forhold til 57 % af dyrene der modtog escitalopram.  
Det konkluderes, at de præsenterede resultater i denne PhD afhandling bidrager 
med vigtig viden, der understøtter det nye systemiske perspektiv i forståelsen af 
ætiologi og patologi af MS og depression. Dette indikerer et paradigmeskifte i 
udvikling, progression og behandling af sygdomme i centralnervesystemet, særligt 
MS og depression, hvor fedtsyremetabolismen spiller en central rolle og baner 
vejen til en ny kur.  
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CHAPTER 1. INTRODUCTION  
This PhD thesis is centered around four manuscripts that collectively focus on 
metabolic alterations involved in the pathogenesis and treatment of central nervous 
system (CNS) diseases. Here, a ‘zoomed-out’ study of well-known mechanisms and 
extract features that are common to all, and features which stand out are presented. 
The following paragraphs introduce the diseases with pathology and current 
treatments. Furthermore, it is explained how genetic, environmental and microbial 
factors connect to all CNS diseases and problems in the balance of energy and 
metabolism of both glucose and lipids. 
1.1. MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is traditionally understood as an inflammatory, autoimmune 
and neurodegenerative disease of the CNS. It is a complex disease characterized by 
pathological features as white matter demyelination, loss of oligodendrocytes, 
reactive gliosis, axonal degeneration, inflammatory plaques and breakdown of the 
blood-brain barrier (BBB) (1–4). 
MS is estimated to affect 400,000 individuals in the United States and between 2.1 
and 2.5 million individuals worldwide with women being predominantly affected 
(5–7). The symptoms of MS are among others dyscoordination, sensory loss, 
weakness, vision loss, and bowel and bladder dysfunction. There are four clinical 
types of MS; relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), 
secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS). RRMS 
is the most common type of MS as it accounts for approximately 85 % of all cases. 
It is characterized by attacks evolving over days to weeks followed by recovery, and 
in between attacks there is no worsening of neurological function (1). This subtype 
may later develop into SPMS in about 65 % of the patients (8). PPMS is 
characterized by steady decline of function from disease onset with no relapses. 
SPMS is characterized by initial relapses with following gradual deterioration of 
neurological function and no acute attacks. The last type of MS is PRMS where 
function declines steadily from disease onset with presence of acute attacks (1).  
The diagnosis of MS is confirmed by magnetic resonance imaging technology, 
which shows white matter lesions of CNS and spinal cord lesions. Ancillary tests 
used in problematic cases are cerebrospinal fluid samples detecting inflammation 
with mononuclear cells and increased levels of immunoglobulins as well as tests of 
visual, auditory and sensory function (9). Today disease-modifying therapies are 
effective in RRMS and only few therapies are effective in PPMS and SPMS (4) 
(Table 1). No current MS therapies, however, reverse the pathological damage or 
cure the disease. They only slow down the immune-mediated inflammation (1). 
Other therapeutic approaches have included statins, which decreases blood 
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cholesterol and peroxisome proliferator-activated receptor (PPAR) agonists treating 
hypertriglyceridemia (10). In order to develop new drugs for MS, it is essential to 
understand the mechanisms of actions of the current drugs (Table 1). 
The etiology of MS remains unknown, though several mechanisms for 
immunoreactivity causing autoimmunity have been proposed (7). The first 
mechanism describes MS triggered in the periphery of the body, while the second 
mechanism involve inflammation triggered by a viral infection as a primary event 
and resulting in infiltrative autoreactive T cells in the CNS as a secondary event 
(11). Normally, most autoreactive T cells are deleted due to central tolerance in the 
thymus where the production takes place. However, if peripheral tolerance is 
abrogated as a consequence of defects in regulatory T cell function, autoreactive T 
cells are activated in the periphery by infections, for example, which can affect the 
immune system in many ways through processes as molecular mimicry, altered 
peptide ligand or bystander activation (11,12).  
Molecular mimicry, postulated to be the key mechanism in CNS autoimmunity, is a 
process by which an encounter with a virus, for example, is recognized by a T cell 
receptor leading to activation of autoreactive T cells that cross-react with self-
antigens or have shared epitopes (7,13). Cross-reactivity between the agent and the 
host is localized at disease-related epitopes, which are peptides of autoantigens like 
the myelin basic protein (MBP) that are presented by the major histocompatibility 
complex (MHC) class II molecules on antigen presenting cells to induce 
autoreactive cluster of differentiation (CD) 4+ T cells. Another proposed 
autoimmune mechanism is known as altered peptide ligand, in which a peptide with 
slightly different composition of amino acids can cause disease (7). An example of 
this mechanism is the post-translational modification termed citrullination, where 
arginine becomes modified to citrulline, an enzyme which naturally occurs on MBP 
(14). Bystander activation is yet another proposed mechanism for autoimmunity 
where a pathogen activates antigen presenting cells, which then stimulate the 
activation and proliferation of autoreactive T and B cells by presenting a self-antigen 
(12). These processes all result in activated autoreactive T cells becoming CD8+ T 
cells, CD4+ T helper (Th) 1 cells, CD4+ Th17 cells, which then migrates into the 
CNS together with B cells and monocytes (11).  
This mechanism of MS etiology is consistent with the pathogenesis investigated in 
the state-of-art in vivo animal model of MS: experimental autoimmune 
encephalomyelitis (EAE) (10). It mimics some of the clinical and pathological 
features in MS, where a CNS antigen, such MBP or myelin oligodendrocyte 
glycoprotein, in an adjuvant is administered together with pertussis toxin producing 
Th1 and Th17 cells. After entering the blood circulation, these cells cross the BBB 
and exert effector functions in the CNS (2,11).  
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Drug Target Mechanism of action Efficacy 
Cladribine 
(15) 
Adenosine 
deaminase 
Depletes peripheral T and B 
lymphocytes  
Lower rates of relapses 
in RRMS 
Ocrelizumab 
(16,17) 
CD20+ B cells Depletes CD20+ B cells Lower rates of disease 
activity and progression 
in RRMS and SPMS 
Alemtuzumab 
(18) 
CD52  Depletes CD52-expressing T and B 
cells via ADCC, CDC and activation 
of pro-apoptotic pathways 
Reduce relapse rates in 
RRMS 
Dimethyl 
fumarate  
(19) 
Nrf2 Activates Nrf2 and suppresses NF-
κB 
Reduce relapse rates in 
RRMS 
Teriflunomide 
(20) 
Dihydroorotate 
dehydrogenase 
Inhibits pyrimidine synthesis for 
DNA replication and reduces T and 
B cell activation, proliferation and 
function 
Reduce relapse rates and 
disability progression in 
RRMS 
Fingolimod 
(21) 
Sphingosine-1-
phosphate 
receptor 
Inhibits lymphocyte egress from 
lymph nodes 
Reduce relapse rates and 
disability progression in 
RRMS 
Natalizumab 
(22) 
α4-subunit of 
α4β1- and 
α4β7-integrins  
Blocks the interaction between 
α4β1-integrin and VCAM-1 on 
endothelial cells resulting in reduced 
leukocyte migration into CNS 
Reduce relapse rates in 
RRMS 
Mitoxantrone 
(23) 
Topoisomerase 
II enzyme  
Inhibits T cell activation, inhibits T 
and B cell proliferation, decreases 
antibody production and deactivates 
macrophages 
Reduce relapse rates and 
progression of disability 
in worsening RRMS and 
SPMS  
Glatiramer 
acetate  
(24) 
MHC Binds to MHC II on APCs and 
displacing peptides from MHC II 
binding site 
Reduce relapse rates, 
disability and 
progression in RRMS 
Interferon-β 
(5,25) 
Interferon 
receptor 
Inhibits proliferation of T 
lymphocytes, proinflammatory 
cytokines, migration of cells across 
BBB, shifts Th1 response to Th2 
response and modulates MHC 
antigens  
Reduce relapse rates in 
RRMS 
Table 1. Overview of food and drug administration (FDA) approved drugs for multiple 
sclerosis (MS) listed by newest drug. ADCC: antibody-dependent cellular cytotoxicity, APC: 
antigen-presenting cell, BBB: blood-brain barrier, CD: cluster of differentiation, CDC: 
complement-dependent cytotoxicity, CNS: central nervous system, MHC: major 
histocompatibility complex, NF-κB: nuclear factor-kappa-light-chain-enhancer of activated B 
cells, Nrf2: nuclear factor erythroid 2-related factor 2, RRMS: relapsing-remitting MS, 
SPMS: secondary-progressive MS, Th: T helper cell, VCAM-1: vascular cell adhesion 
molecule-1. 
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Besides the T cells, B cells and their production of antibodies are also involved in 
MS pathology (1). There is limited knowledge about the role of the antibody-antigen 
response in the induction and progression of MS, however the presence of 
intrathecal antibodies, known as oligoclonal bands, in the cerebrospinal fluid makes 
an obvious argument for the involvement of B cells in the pathogenesis (26). The 
mechanisms by which loss of tolerance to self-proteins result in the production of 
autoantibodies include altered peptide ligand response and epitope spreading (14). 
An incomplete conceptual framework for the understanding of all the factors leading 
to imbalance in immune homeostasis, demyelination and progressive neurological 
symptoms (9) indicates that parts of the etiology and pathology remains unexplored 
and undiscovered. 
1.1.1. COMORBIDITIES  
Comorbidities, such as depression, diabetes, hyperlipidemia and hypertension, are 
common in patients with MS and opens up an important and increasing area of 
interest (27). These comorbid conditions are associated with increased progression 
of disability (28), delay of diagnosis or disease severity at diagnosis (29), as well as 
with increased risk of death (30). These factors can potentially describe the 
heterogeneity of disease outcomes (28) and further highlights the complexity of the 
treatment regimen of MS patients (27).  
Depression is experienced in up to 60 % of the MS patients during disease course 
and correlates with increased suicide rates (31–34). It is controversial whether 
abnormalities in the immune system occur prior to onset of depression or as a 
secondary event to inflammation (35). Immune system abnormality is suggested as a 
contributor in depression, as increased levels of the pro-inflammatory cytokines 
tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 have been found (36). 
Cytokines are activators of the hypothalamic-pituitary-adrenal (HPA) axis leading to 
secretion of glucocorticoids and intensification of the stress-response system (37). It 
is unknown whether depression influences the neurobiological course of MS 
however stressful life events precede exacerbations (38). Vascular comorbidities 
such as diabetes, hyperlipidemia and hypertension have adverse effects on MS 
pathology resulting in increased cognitive decline, brain atrophy, increased 
peripheral inflammation and oxidative stress (28).  
1.2. DEPRESSION 
Depression is a common psychiatric disorder, which affects up to 15 % of the 
population worldwide (39). It is characterized by loss of pleasure (anhedonia), 
sadness, hopelessness, cognitive impairment and suicidal thoughts (39,40). The 
diagnosis of depression is confirmed based on the presence of at least five of the 
following symptoms in the Diagnostic and Statistical Manual present daily or almost 
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daily for at least two weeks (41). The symptoms include: changes in weight and 
appetite, insomnia or hypersomnia, loss of energy, loss of interest, psychomotor 
agitation, worthlessness feelings, diminished ability to concentrate and think, 
thoughts of death and suicidal ideation. The severity of the disorder is categorized as 
mild, moderate and severe according to disruption of social and occupational 
functions (41). As opposed to other conditions, depression is diagnosed based on 
subjective ranges of symptoms and not on objective diagnostic tests, which 
highlights the heterogeneity of the disease and difficulties in making a diagnosis.   
The areas involved in the pathogenesis of depression are still unknown, however 
neuropathological changes in the prefrontal cortex, hippocampus, striatum (ventral 
striatum and nucleus accumbens), amygdala and hypothalamus are associated with 
the symptoms present in depression (42,43). The prefrontal cortex and hippocampus 
are related to cognitive impairments as memory loss, feelings as worthlessness and 
hopelessness, and suicidal ideation (42). The ventral striatum, nucleus accumbens 
and amygdala are associated with rewards in response to stimuli mediating 
anhedonia, reduced motivation and anxiety (42,43). The hypothalamus is involved 
in changes in sleep patterns and appetite (42). 
The etiology of depression has not been elucidated yet, however different 
hypotheses have been proposed: the monoamine, the neurotrophin and the cytokine 
hypothesis. The monoamine hypothesis involves decreased availability of 
neurotransmitters such as serotonin, dopamine and noradrenaline in the CNS. These 
low levels of monoamines have been the ground for developing selective serotonin 
reuptake inhibitors and serotonin noradrenaline reuptake inhibitors, which are 
antidepressants increasing the levels of serotonin and noradrenaline, respectively 
(39). In the neurotrophin hypothesis it is hypothesized that depression is a result of 
decreased levels of neurotrophic factors, which are growth factors responsible for 
the regulation of neuronal plasticity in the brain (44). An important, abundantly 
expressed, neurotrophic factor is brain-derived neurotrophic factor (44,45). Under 
conditions of stress the expression of brain-derived neurotrophic factor and other 
neurotrophic factors are decreased leading to alterations in hippocampal structure 
and function (44,46). The cytokine hypothesis posits that depression is manifested 
by increased levels of pro-inflammatory cytokines, acute phase proteins, 
chemokines and adhesion molecules (47). These pro-inflammatory cytokines get 
access to the brain where they interact with the metabolism of monoamines 
(serotonin, dopamine and noradrenaline), neuroendocrine function and neural 
plasticity. The effect of cytokines on the metabolism of neurotransmitters involves 
the release of cytokines, chemokines, reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) by microglia in the brain (48). Cytokines such as TNF-α, 
interferon-γ, IL-1 and IL-6 activates indoleamine 2,3 dioxygenase resulting in 
breakdown of tryptophan, which is the precursor for serotonin, into kynurenine. This 
mechanism is suggested to cause the low availability of serotonin (49). In addition, 
the low levels of dopamine are caused by cytokines influencing tetrahydrobiopterin, 
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an enzyme involved in dopamine synthesis, via nitric oxide production (48). 
Furthermore cytokines have an effect on neuroendocrine function, where alterations 
in the glucocorticoid receptor with following negative feedback regulation of HPA 
axis leads to glucocorticoid resistance and increased cortisol levels (50). Normally, 
cytokines as TNF-α, IL-1 and IL-6 provide support to neurogenesis, however 
prolonged activation of these can cause several abnormalities such as decreased 
neurogenesis, oxidative stress, apoptosis of astrocytes and oligodendrocytes (51).  
Different risk factors contributing to the pathogenesis of depression have been 
proposed. Environmental factors, for example, such as stress is thought to be a 
trigger in the development of depression in genetically susceptible individuals 
(52,53). Internal stress factors include interpersonal, financial, achievement and 
legal events along with more external stress factors such as hormonal challenges and 
injuries seem to also be triggers (54,55). Stressful events formed the basis of a 
rodent animal model of depression, the chronic mild stress (CMS) model. This state-
of-art validated model shows that involving realistic stress factors contribute to the 
induction of depression in humans as well (52,53,56). The theoretical rationale 
behind the CMS model is a defective reward system which stimulates the cardinal 
symptom of depression, anhedonia (57,58). This causes a decrease in responsiveness 
to reward measured as suppressed preference of sucrose solution. Repetitive readout 
of the hedonic status of the animals and of the depression-like status are then 
measured (53,55,57). 
Drug Target Mechanism of action 
SSRIs 
(59,60) 
Serotonin transporter Inhibits the reuptake of serotonin by presynaptic 
transporters resulting in increased serotonin levels 
 
SNRIs  
(61) 
Serotonin and 
noradrenaline transporter  
Inhibits the reuptake of serotonin and noradrenaline by 
presynaptic transporters resulting in increased levels of 
both neurotransmitters 
TCAs 
(53,61) 
Plasma membrane 
transporters of serotonin 
and noradrenaline 
Inhibits the reuptake of noradrenaline (and serotonin) 
by presynaptic transporters resulting in increased levels 
of these neurotransmitters  
MAOIs 
(61) 
Monoamine oxidase  Inhibits monoamine oxidase resulting in increased 
concentrations of monoaminergic neurotransmitters 
(serotonin, noradrenaline and dopamine) 
Table 2. Overview of antidepressant classes of drugs for depression. SSRIs: selective 
serotonin reuptake inhibitors, SNRIs: serotonin-norepinephrine reuptake inhibitors, TCAs: 
tricyclic antidepressants, MAOIs: monoamine oxidase inhibitors. 
Currently many different classes of antidepressant drugs exist, all of which have 
been tested in the CMS model of depression. These classes include selective 
serotonin reuptake inhibitors, tricyclic antidepressants and monoamine oxidase 
inhibitors (52) (Table 2). In order to reverse the CMS-induced symptoms in rodents, 
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it typically requires three to four weeks of antidepressant treatment (62). However, 
approximately 50 % of the anhedonic animals reject the antidepressant treatment, 
which is similar to the therapeutic treatment in humans (63). The antidepressant 
treatments available today have only showed moderate response rates, as up to 40 % 
of patients do not respond to the treatment (61,64). 
1.3. ENERGY METABOLISM OF THE BRAIN 
Metabolic pathways have been overlooked in the past, despite the importance of 
these in both health and disease. Therefore, the metabolic pathways of the brain, 
though similar to other tissues, will be reviewed in the following paragraphs. The 
concept behind energy homeostasis denotes processes managing intake, storage and 
utilization of substrates for the maintenance of stable energy levels (65). In order to 
maintain the energy homeostasis in the brain there is a competing relationship 
between oxidation of glucose and fatty acids called the glucose-fatty acid cycle 
(66,67).  
1.3.1. GLUCOSE METABOLISM 
Glucose is the primary energy source in the brain, where a constant supply of 
glucose by tight metabolic regulation is needed to sustain physiological brain 
function (68–70). Glucose provides functions through neuroenergetics, 
neurotransmission, energy storage, biosynthesis of amino acids, monosaccharides 
and carbohydrates, and oxidative defense. The energy-producing pathways using 
glucose include first glycolysis, in which glucose is converted to pyruvate, and then 
oxidative glucose metabolism converting pyruvate to carbon dioxide via the Krebs 
cycle and the electron transport chain (71).  
Glucose requires to be transported across the endothelial cells of the BBB achieved 
by sodium-independent facilitative glucose transporters (GLUTs) localized at the 
luminal and abluminal side of the cells (68,72). Afterwards it is transported from the 
extracellular space in the brain through the plasma membranes of neurons, 
astrocytes, oligodendrocytes and microglia, which is also facilitated by GLUTs 
(72,73). The expression of the different isoforms of GLUTs is cell type specific (70). 
GLUT1 mediates glucose uptake into astrocytes, oligodendrocytes and microglia, 
whereas GLUT3 mediates uptake into neurons (68,72). Once the glucose is taken 
up, the brain rapidly catabolizes the glucose (70). 
There are different pathways for the glucose metabolism however the initial step is 
common for all pathways (74). The initial step in metabolism involves the enzyme 
hexokinase 1, involved in glycolysis, which phosphorylates glucose to glucose-6-
phosphate, the precursor for glycogen (Figure 1). Then it either can be converted 
into glycogen for storage creating a glucose pool maintaining a balance between 
influx, efflux and metabolism. Alternatively, it can be converted to fructose-6-
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phosphate and continue in the glycolytic energy production with end products of 
pyruvate, or lastly it can enter the pentose phosphate pathway generating 
nicotinamide adenine dinucleotide phosphate, a precursor required for lipid 
synthesis. When pyruvate enters the mitochondria through the pyruvate 
dehydrogenase complex it is converted into acetyl-CoA and metabolized in the 
Krebs cycle (68,70,71,74).  
The glucose homeostasis is regulated by neuronal and hormonal components that 
control production and utilization of glucose. A neuronal component involves 
glucose-sensing neurons in the hypothalamus and a hormonal component involves 
insulin, which acts on the melanocortin system, thereby regulating the glucose 
homeostasis (65,75,76).  
The idea of the glucose-fatty acid cycle, which functions as a competing relationship 
due to a flexible choice of energy substrate in tissues, is that under sparse levels of 
glucose during conditions of fasting or exercise, the energy source will switch from 
using glucose to the alternative energy sources as fatty acids and ketone bodies. The 
purpose of this relationship is saving glucose for the brain when energy demands are 
scarce (67).  
1.3.2. LIPID METABOLISM 
Lipid metabolism is of particular importance for the brain due to the high lipid 
concentration exceeded only by adipose tissue (77). Lipids are divided into eight 
categories; fatty acids, glycerolipids, glycerophospholipids, sphingolipids, sterol 
lipids, prenol lipids, saccharolipids and polyketides (78), where fatty acids constitute 
the major focus. 
Fatty acids are essential lipids, which consist of a carbon chain with a carboxylic 
acid group. These are divided into subtypes based on the carbon chain length. Short-
chain fatty acids have 2-4 carbon atoms, medium-chain fatty acids consists of 6-12 
carbon atoms, while long-chain fatty acids have 14-18 carbon atoms and lastly very 
long-chain fatty acids consist of >18 carbon atoms (79). Furthermore, fatty acids can 
be classified as saturated or unsaturated, where saturated fatty acids are defined by 
carbons saturated with hydrogen atoms and no double bonds, contrary to unsaturated 
fatty acids which have double bonds and the number of these determines whether it 
is mono- or polyunsaturated fatty acids (PUFAs). Saturated fatty acids and 
monounsaturated fatty acids are synthesized in the brain, whereas PUFAs are 
supplied by the blood (80).  
PUFAs are important for the brain as they serve as vital molecules for membrane 
structure and cell signaling (79). Predominant PUFAs in the brain are for example 
omega-6 arachidonic acid and omega-3 docosahexaenoic acid. Fatty acids can be 
free or esterified to lipids such as phospholipids and cholesterol, where fatty acids in 
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the brain mostly under undergo esterification to phospholipids for example palmitate 
and oleate enriching the myelin (80).  
There exist three pathways in the metabolism of lipids. Since lipids are insoluble in 
water, transport proteins, called lipoproteins, are a necessity. The pathways include; 
the exogenous, the endogenous and the reverse cholesterol pathway (81). The 
exogenous pathway takes place in the enterocytes of the small intestine, where 
chylomicrons are synthesized in a process where triacylglycerol, cholesterol esters 
and apolipoprotein are assembled by microsomal triglyceride transfer protein. After 
leaving the enterocytes, the chylomicrons enter the lymphatic system and emulsifies. 
Apolipoprotein from high-density lipoprotein (HDL) activates the endothelial cell 
walls leading to cleavage of triacylglycerol and release of free fatty acids used for 
energy utilization. In this process chylomicron remnants are formed and taken up by 
the liver and further used in the endogenous pathway. The endogenous pathway 
therefore begins in the liver and involves formation of very low-density lipoprotein 
(VLDL) from free fatty acids and cholesterol esters. Microsomal triglyceride 
transfer protein assembles triacylglycerol, cholesterol esters and apolipoprotein 
producing VLDL, which leaves the liver and enters the serum. Lipoprotein lipase 
breaks down VLDL into oxidized lipoprotein and intermediate dense lipoprotein 
resulting in free fatty acid used for energy utilization or storage in adipocytes. The 
end product is low-density lipoprotein molecules containing cholesterol used for the 
synthesis of sterol lipids, or uptake into macrophages undergoing apoptosis or 
emptying the lipids by the reverse cholesterol pathway. The cholesterol reverse 
pathway involves removal of excess cholesterol esters from the peripheral tissue by 
the binding of HDL to a receptor on macrophages resulting in cholesterol ester 
efflux transport to the liver reusing the HDL for VLDL synthesis or catabolism (81).  
Peroxisomes, which are specialized organelles, serve as a central regulator of the 
lipid metabolism through several mechanisms like for example breakdown of long-
chain fatty acids necessary for further use in energy production in the mitochondria 
(81), which are the main site for fatty acid metabolism. The uptake of fatty acids in 
the mitochondria is mediated by several membrane proteins (67). Transport of fatty 
acids from the blood to the brain necessitate passage across the BBB and can occur 
by passive diffusion or by protein-mediated transport pathways dependent on the 
molecular size of the lipids (82). Short-chain and medium-chain fatty acids have 
high permeability and cross the plasma membrane easily, whereas long-chain fatty 
acids are less soluble and therefore need fatty acid transport proteins (FATPs) (83). 
FATPs are integral transmembrane proteins localized in the plasma membrane that 
enhance the uptake of long-chain and very long-chain fatty acids (84). FATP1 and 
FATP4 are predominantly expressed in the brain (83,84). Most of the FATPs 
possess acyl-CoA synthase activity, which converts fatty acids to fatty acyl-CoA 
after translocation through the plasma membrane (67) (Figure 1). As the outer 
mitochondrial membrane is impermeable to fatty acyl-CoA it uses the carnitine 
shuttle, where the first step includes carnitine palmitoyl transferase (CPT) 1, which 
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converts fatty acyl-CoA into acyl-carnitine. Carnitine acyl-carnitine translocase 
transports acyl-carnitine through the mitochondrial membrane. The second step of 
the shuttle involves CPT2, localized at the inner mitochondrial membrane, which 
reconverts acyl-carnitine into acyl-CoA and carnitine. Once inside the mitochondria, 
the degradation of acyl-CoA into shorter units by β-oxidation takes place. The β-
oxidation is a cyclic pathway with production of a shortened acyl-CoA, an acetyl-
CoA, a nicotinamide adenine dinucleotide and a flavin adenine dinucleotide after 
each cycle. The turnover of acyl-CoA re-enters β-oxidation (67). After import of the 
fatty acids, catabolism occurs in the mitochondrial matrix by several steps 
metabolizing long-chain acyl-CoAs to short-chain acyl-CoAs (67,85–87). CPT1 and 
CPT2 have a clear cut function allowing β-oxidation of long-chain fatty acids, such 
as palmitoyl-CoA and oleoyl-CoA, to occur with the end product acetyl-CoA 
important for the Krebs cycle in the mitochondria (67,85). The energy produced in 
the Krebs cycle is transferred to the electron transport chain resulting in production 
of adenosine triphosphate (ATP). Reversible inhibition of CPT1 activity is exerted 
by malonyl-CoA, thereby possessing a regulatory role of the fatty acid catabolism 
(66,85).  
Other regulators of the fatty acid metabolism involve hormones and transcription 
factors (88). Insulin is secreted in response to high blood glucose levels resulting in 
increased transport of glucose by translocation of the GLUTs from intracellular 
vesicles to the plasma membrane, which also affects the lipolysis by preventing the 
availability of fatty acids as energy substrate (67,89). PPARs, which are nuclear 
receptor proteins with transcriptional function widely expressed in the brain, control 
expression of genes important for both glucose and lipid metabolism along with the 
function and numbers of peroxisomes (81,89,90). PPARs use free fatty acids as 
ligands, thus activating PPAR binding to peroxisome proliferator response element 
resulting in increased expression of target genes (81). PPARs act as metabolic lipid 
sensors, which make them important transcriptional regulators of the energy 
balance, the fatty acid metabolism, the glucose homeostasis and insulin sensitivity 
(89).  
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Figure 1. Transport of glucose and fatty acids. Glucose enters the cell via GLUT and is 
phosphorylated to glucose-6-phosphate by HK1 followed by conversion to fructose-6-
phosphate. Fructose-6-phosphate is converted to pyruvate by PFK1. PDH transforms 
pyruvate into acetyl-CoA in the mitochondria. Acetyl-CoA is used in the Krebs cycle. Fatty 
acids enter the cell via FATP, which possess acyl-CoA synthase activity and converts fatty 
acids into fatty acyl-CoA. CPT1 facilitates the transport across the outer mitochondrial 
membrane by converting fatty acyl-CoA to acyl-carnitine. CPT2 reconverts acyl-carnitine 
into acyl-CoA and carnitine. Acyl-CoA is used in β-oxidation producing acetyl-CoA. Acetyl-
CoA from glucose pathway and lipid pathway is used in the Krebs cycle. The energy produced 
in the Krebs cycle passes to the ETC, where it is converted into ATP. Inhibitory mechanisms 
include inhibition of PDH by acetyl-CoA and inhibition of CPT1 by malonyl-CoA (red 
inhibiting arrow). ATP: adenosine triphosphate, CPT1: carnitine palmitoyl transferase 1, 
CPT2: carnitine palmitoyl transferase 2, ETC: electron transport chain, FATP: fatty acid 
transporter, GLUT: glucose transporter, HK1: hexokinase 1, PDH: pyruvate dehydrogenase 
complex, PFK1: phosphofructokinase 1.  
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1.4. ENERGY METABOLISM OF THE IMMUNE SYSTEM 
The different T cell phenotypes have unique metabolic demands thus switching 
reversibly between quiescent and proliferative states promoting activation of 
different metabolic pathways (91).  
The primary energy source of T cells is glucose, which is required for growth, 
activation and proliferation (92). The glucose metabolism is activated by signals 
from T cell receptor and a co-stimulatory signal via CD28. This triggers 
phosphatidylinositol 3´-kinase (PI3K) leading to activation of protein kinase B 
(Akt), also known as the PI3K-Akt pathway, which regulates the energy metabolism 
(91). Akt increases the glucose uptake by upregulation of GLUT1 on T cells. The T 
lymphocytes Th1, Th2 and Th17 all express GLUT1 thus possessing high glycolytic 
levels. In contrast, regulatory T cells express low levels of GLUT1 indicating low 
glycolytic levels and the importance of fatty acid oxidation as energy source (93). 
Furthermore, Akt stimulates the activity of the rate-limiting enzyme hexokinase 
important for glycolysis (91). B cell and natural killer cells possess similar 
metabolic signaling pathways, as these initiated in T cells, though these are activated 
via CD19 and DNAX-activating protein 10, respectively, instead of CD28.   
In addition to the key protein kinase Akt, involved in metabolic control pathways, 
there is another kinase, adenosine monophosphate (AMP)-activated protein kinase 
(AMPK), which acts as an energy sensor and is activated by serine-threonine kinase 
11. The activation is dependent on the levels of AMP and activated in response to 
ATP depletion. This AMPK signaling pathway regulate the metabolism and 
differentiation of CD4+ T cells into effector T cells or regulatory T cells relying on 
specific metabolic demands, in particular glycolytic and fatty acid metabolism, 
respectively. The result is suppression of anabolic mechanisms and stimulation of 
catabolic mechanisms such as fatty acid oxidation by decreasing the levels of acetyl-
CoA carboxylase, which then stimulates the activity of CPT1 and thereby ATP 
production (91,94–96). All these different pathways indicate that metabolism is 
fundamental in the determination of cell fate, and is important in both health and 
diseased conditions.  
1.5. GENETIC, ENVIRONMENTAL AND MICROBIAL FACTORS 
The etiology of MS remains unknown, however it is now accepted as a 
multifactorial disease influenced by genetic, environmental and microbial factors 
(4,8). Children or siblings of patients with MS have a risk of 3-5 % for getting MS 
and monozygotic twins have an even higher risk of 25 % (8). These data show that 
there is a genetic component in developing MS. Human leukocyte antigen (HLA) 
variants are associated with immune response genes, whereas non-HLA variants are 
associated with genes in immune activation and tolerance (4). The HLA-DR beta I 
(DRB1)*1501 allele in MHC-II is a dominant risk factor for MS with an odds ratio 
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of approximately 3 (4,97). Over time more comprehensive investigations were 
conducted, thereby identifying several alleles related to MS (8,98). More than 50 
loci were found susceptible for an association with immune system including genes 
for IL-2 receptor alpha chain and IL-7 receptor alpha chain, cytokine pathways 
including a gene for TNF-α, and finally associated with co-stimulatory molecules 
such as genes for CD80 and CD86 (8). In contrast to these mutations for getting MS, 
mutations with protective effects against developing MS exist. These mutations 
include CPT1A P479L (99) and CPT1A G710E (100,101) and will be elaborated 
further. 
These findings indicate a strong genetic component, however genetic associations in 
the development of MS are not enough and environmental factors also play a role. 
Environmental factors include geographic variations where increasing latitude 
results in increased MS development, as well as vitamin D deficiency increases the 
risk of MS development due to the correlation between low vitamin D levels and 
increased latitude (8). Other environmental factors include among others smoking, 
obesity, Epstein-Barr virus infection and gut microbiota changes. Risk factors as 
vitamin D, smoking, diet and stress are associated with gut microbiome dysbiosis, 
since diminished intake of vitamin D causes changes in the immune response by 
increasing the regulatory T cell amount and decreasing the T cell amount in the gut. 
Smoking causes changes in the composition of the microbiome (102). Diet and 
stress enhance the gut permeability mediated by bacteria that drive the immune 
response and affect the CNS (103,104). These mentioned risk factors increases gut 
permeability and leads to the transfer of gram-negative bacteria initiating an immune 
response (103).  
Microbiota are able to produce and release neuroregulatory factors such as 
dopamine, noradrenaline and acetylcholine important neurotransmitters for 
preventing depression (103), in this context, enhanced gut permeability has been 
found to be related to depression. The role of genetics in depression is poorly 
understood and limited data are available (35). Although depression is thought to be 
a result of both genetic predisposition and environmental factors as stress, head 
injury, family conflicts, depression is only triggered in genetically susceptible 
individuals (53,105).  Examples of investigated genes implicated in depression are 
serotonin transporter, serotonin receptor 1A and 2A, involved in the synthesis of 
serotonin and apolipoprotein E (APOE) involved in the catabolism of lipoproteins 
(106).  
1.6. NEW MODEL OF CENTRAL NERVOUS SYSTEM DISEASES  
The traditional way of thinking the pathogenesis of CNS diseases has changed as it 
rather has become evident that more complex systems underlies the pathology, 
where MS and depression constitute the major focus in this PhD thesis. Therefore, 
this opens a question if there is a change of paradigm towards treatments of CNS 
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diseases with metabolic pathways as the central part? This will be described in the 
following paragraphs. 
1.6.1. LIPID METABOLISM AS A CENTRAL PART 
Altered metabolism is proposed to underlie the pathogenesis of several diseases 
affecting different cellular mechanisms as inflammation, oxidative stress, 
mitochondrial dysfunction, iron accumulation, insulin resistance and microbiota. 
Inflammation is present in several diseases and associated with both MS and 
depression, which makes the understanding of the impact of lipids on immune cells 
an important part (107). Lipids serves as regulators of immune cell polarization and 
proliferation of T lymphocytes is dependent on energy produced by both glycolysis 
and β-oxidation (107,108). Pathogen entrance and consequently inflammation 
mediates activation of T cells, which then differentiate into effector T cells or 
regulatory T cells, having specific metabolic demands, required for the specific 
environment. When an immune response is initiated and T cells become activated β-
oxidation decreases while glycolysis increases. At the end of an inflammatory 
response the metabolic state switches to decreased glycolysis and increased lipid 
oxidation, conditions favored by memory T cells (93). 
Oxidative stress is a contributor in the pathogenesis of neurodegenerative diseases as 
MS (109), where lipids serve as the major target. Since the brain contains the highest 
concentration of lipids next to adipose tissue and with the fact that fatty acids are 
targets for lipid peroxidation it underlines that the brain, more specific neurons and 
oligodendrocytes, is particularly vulnerable to oxidative stress and β-oxidation 
(98,109). Though, it can also cause damage to nucleic acids, proteins and 
carbohydrates resulting in necrosis and apoptosis (110). ROS and RNS generated by 
macrophages and microglia cause damage in active MS lesions resulting in 
structural changes in myelin proteins, which become targets of immune cells as they 
are recognized as foreign antigens (98). ROS such as superoxide anion radicals, 
hydrogen peroxide and hydroxyl radicals are produced through oxidative 
phosphorylation by processes as mitochondrial respiratory chain, nicotinamide 
adenine dinucleotide phosphate oxidases and monoamine oxidases (109). Oxidative 
stress results from ROS production exceeding the detoxification capacity of these 
reactive intermediates of the cell (109). The brain consumes high amounts of oxygen 
for production of energy and has low levels of antioxidants, which makes it even 
more vulnerable to oxidative stress (110). Moreover, ROS and RNS are able to 
activate transcription factors such as nuclear factor-kappa-light-chain-enhancer of 
activated B cells and nuclear factor erythroid 2-related factor 2 (Nrf2) resulting in 
upregulated expression of TNF-α responsible for activation of neutrophils sensing 
an infection (111) and induction of antioxidant enzymes as heme oxygenase-1 (HO-
1) scavenging free radicals and removing damaged proteins (2).  
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The mitochondria are the energy factories of the cells and besides this they are also 
important for cellular functions such as fatty acid oxidation, glycolysis, amino acid 
biosynthesis and apoptosis. Oxidative metabolic mechanisms generate almost all of 
the ATP in the cell, which underpin the importance of these (98). However excess 
amounts of fatty acids can results in mitochondrial dysfunction further contributing 
to macrophage inflammation and production of superoxide (98,107). Normal 
mitochondrial respiration produces by-products as ROS and requires detoxification. 
Though, the lack of protective proteins results in mutated mitochondrial DNA in 
case of increased ROS levels, thereby compromising oxidative phosphorylation, 
which results in collapse of the mitochondria (2).  
Iron is fundamental to brain metabolism by processes as oxidative phosphorylation 
and myelination. Normally, iron is present in the brain parenchyma where it is 
predominantly stored in ferritin (FT) as non-heme iron (ferric iron), whereas a small 
amount is present as heme iron (ferrous iron) (112,113). There are two subunits of 
FT: heavy chain (FTH) and light chain, which are both expressed by 
oligodendrocytes (114). The transport of ferrous iron to other cells in the CNS is 
facilitated by transferrin, divalent metal transporter and ferroportin. If ferrous iron is 
not required it will be oxidized into ferric iron and stored in FT (113). In contrast, 
disrupted brain iron homeostasis in MS, for example, leads to accumulation of 
ferrous iron generating ROS, which are harmful to lipids. Moreover, the 
mitochondria are vulnerable to elevated ROS levels and dysfunction of the 
mitochondria is related to oxidative damage in MS. The oligodendrocytes, which are 
the main targets of inflammation in MS, are in particular vulnerable to such 
mitochondrial dysfunction and ROS (112).  
Insulin resistance is caused by alterations in metabolism in particular characterized 
by increased fatty acid oxidation and decreased glycolysis according to the 
traditional view (88,115–117). Following increased fatty acid oxidation, an 
increased production of acetyl-CoA from fatty acid catabolism leads to inhibition of 
pyruvate dehydrogenase. Consequently, levels of glucose-6-phosphate are elevated, 
which further inhibits hexokinase, which is important for the glucose uptake 
(88,116,118,119). However other mechanisms are suggested to cause insulin 
resistance. It is proposed as a reverse mechanism of the traditional glucose-fatty acid 
cycle describing the glucose metabolism as the controlling part of the rate of fatty 
acid oxidation in which glucose or insulin limits the entrance of long-chain fatty 
acids into the mitochondria by inhibiting carnitine acyltransferase. This is different 
from the traditional mechanism, where it is proposed to be a consequence of a defect 
in the glucose oxidation rather than increased fatty acid oxidation (115). 
Additionally, a defect in GLUT4 and hexokinase activity mediates inhibition of 
glycogen synthesis caused by fatty acid oxidation (120). This failure in the capacity 
of metabolism stimulates oxidative stress with increased ROS levels, which plays an 
important role in situations of altered insulin secretion and serves as a contributor to 
insulin resistance (121). Both insulin resistance and oxidative stress are suggested as 
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comorbidities in MS particularly SPMS contributing to disease disability and 
progression (122).  
Microbiota is important for tissue development, metabolism, immune system and 
nutrient synthesis (123). The gut microbiota is able to synthesize and secrete 
vitamins such as vitamin B12, folate and biotin supporting development of the CNS, 
endothelial cell growth and regulation of the immune system (102). Moreover it can 
control signals from the brain via the microbiome-gut-brain axis through the 
interaction of metabolic, immune system, CNS and endocrine pathways (102). 
Molecular patterns such as ATP and short-chain fatty acids are proposed to play a 
role in the interaction between microbiota and the immune system (123). Short-
chain fatty acids, metabolized by gut bacteria, serve as a link between the immune 
system and the microbiota, as they provide beneficial effects to the metabolism 
through the involvement in cellular processes as gene expression, proliferation, 
differentiation and apoptosis (123,124). Short-chain fatty acids stimulate expansion 
of protective regulatory T cells. In contrast, long-chain fatty acids stimulate 
pathogenic T cell differentiation to Th1 and Th17 cells in the gut and can thereby 
induce inflammation in the CNS (125). Therefore loss of balance between immune 
system and microbiota interactions can cause inflammatory diseases and infections 
(123).  
Lipids play a crucial role in health and disease as alterations in lipid metabolism are 
associated with both neurodegenerative diseases and neurological disorders 
(77,98,110,126). In neurodegenerative diseases such as MS low levels of PUFAs 
have been found, which can be related to the function of PPARs to which PUFAs 
serve as ligands. This results in upregulated lipid metabolism and enhancement of 
glucose catabolism (81). In neurological disorders such as depression changes in the 
composition of serum lipids have been found. These changes include low levels of 
HDL cholesterol, which is a hallmark of depression, low total cholesterol levels and 
low HDL cholesterol:cholesterol ratio suggesting impairment of efflux transport of 
cholesterol from tissue to liver, as HDL particles are important for the transport of 
cholesterol (126). Given that the lipid metabolism plays a pivotal role in energy 
homeostasis, it is tempting to hypothesize that dysregulation of this may underlie 
diseases of the CNS.  
1.6.2. PHARMACOLOGICAL INHIBITION OF LIPID METABOLISM  
CPT1 is located in the outer mitochondrial membrane, where it serves as the 
regulatory site for fatty acid oxidation. Inhibitors of CPT1 are among others 
malonyl-CoA (127). Structurally, CPT1 has two transmembrane domains anchoring 
the enzyme. The active site placed at the C-terminal domain is localized at the 
cytosolic site of the outer mitochondrial membrane (85). Although the exact role of 
CPT1 in CNS diseases is not known it can be hypothesized that there is a link 
between CPT1-mediated lipid transport and these diseases due to its central role in 
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cellular energy production from lipids. This in combination with the fact that the 
fatty acid metabolism is dysfunctional in MS and the lipid level in MS patients and 
depressed patients are reduced. Therefore, inhibition of lipid metabolism through the 
rate-limiting enzyme in fatty acid oxidation, CPT1, could be a potential target for 
treating diseases (14,55,81) and several pharmacological approaches of CPT1 
inhibitors exist, such as perhexiline (128,129), teglicar (130) and etomoxir (14). 
Etomoxir is a potent blocker of CPT1, which is rate-limiting for β-oxidation and 
thus lipid metabolism. Etomoxir is functioning as a CPT1 antagonist, which 
specifically binds to CPT1, thereby preventing formation of acyl-carnitine necessary 
for acyl-CoA transport into the mitochondria (14,55,131). Pharmacological 
inhibition of etomoxir induces shift in metabolic pathways favoring glucose 
metabolism as primary energy source rather than lipid metabolism (117,132).  
It has been tested as a pharmacological treatment for diabetes mellitus with the 
result of a reduced hepatic glucose production thereby reducing fasting blood 
glucose, decreasing triglyceride levels and blocking fatty acid oxidation (117). It has 
also shown effects in myocardial ischemic injury where etomoxir stimulated the 
glucose utilization by overcoming fatty acid oxidation (132). However, etomoxir can 
be provided as a new pharmacological treatment regimen for CNS diseases such as 
MS and depression aiming at both immune system and metabolism contrary to the 
current disease-modifying therapies for MS that solely have been effective in RRMS 
though only revealing symptomatic effects and not reversing the pathological 
damage and most importantly not curing the disease, and to antidepressant 
treatments, which are inefficient in up to 40 % of the patients (61,64). This suggests 
etomoxir as a novel potential target for MS as well as depression. 
1.6.3. GENETIC INHIBITION OF LIPID METABOLISM  
Regulation of the mitochondrial fatty acid metabolism primarily involves CPT1, 
which is expressed in various tissues depending on the particular isoform. The 
protein CPT1A is expressed in the liver, brain, kidney, lung, spleen, intestine, 
pancreas and ovary (87). CPT1B is expressed in muscle, heart, adipose tissue and 
testis, whereas CPT1C is expressed in the brain (87,133).  
The genes CPT1A, CPT1B and CPT1C are localized to human chromosomes 
11q13.1-q13.5, 22q13.31-q13.32 and 19q13.33, respectively (133,134). The human 
CPT1A gene has an open reading frame of 2319 base pair (135) and CPT1B has an 
open reading frame of 2316 base pair (136). 
Several human mutations in CPT1A are identified. In this PhD thesis the major focus 
constitutes two of those mutations. The first is a missense mutation at nucleotide 
position 1436 C to T predicting a substitution of proline for a leucine at codon 479 
(P479L) (99). This variant has 22 % residual activity of the CPT1A protein 
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(137,138). Carriers of CPT1A P479L are identified among Canadian and Greenland 
Inuits. This frequency of the homozygous mutant allele is high in the Inuits in 
Canada (93 %), in Nunavut (81 %) and of Greenland (73 %), when taken both 
homozygous and heterozygous mutant alleles the frequency is up to 98 % (99,139). 
The second is a mutation at nucleotide position 2129 G to A predicting a substitution 
of glycine for a glutamic acid at position 710 (G710E) (100,101). This mutant 
CPT1A is totally inactive, thereby dramatically impairing the catalytic function 
(101). Carriers of CPT1A G710E are expressed among the Hutterite community 
considered as a genetic isolated population similarly to the Amish (100). 
CPT1A deficiency is a rare disorder of mitochondrial fatty acid β-oxidation and is 
inherited as an autosomal recessive disease (100,101). The symptoms comprise 
hypoketotic hypoglycemia, hepatomegaly, seizures and sudden death and are usually 
triggered by exogenous stress factors as fasting, fever and illness (101,138), thus 
making these people more susceptible to infection. Since the catalytic activity of 
CPT1A is only partially lost in the Inuits, these are expected to have milder clinical 
consequences compared to the Hutterites, which have lost the enzymatic activity of 
CPT1A completely. This could be explained by the hindered ability of memory T 
cells to protect against recurring infections, as these cells are dependent on β-
oxidation, which are decreased in these cases (140). 
On the other hand, the prevalence for MS (141,142) and depression (143,144) found 
in the northern indigenous populations, the Inuits and the Hutterites, is remarkably 
low compared to the non-indigenous Canadian population (145). The prevalence of 
MS in the Inuit population is 1 per 50,000 (142) and 1 per 1,100 in the Hutterite 
population (141) compared to the estimated MS prevalence of 240 per 100,000 in 
Canada (145). The same tendency applies for depression with 3 % in the Inuits (144) 
and 0.18 % in the Hutterites (143), which can be compared to the prevalence in the 
Canadian population of 16 % (144). These findings propose a significant role of 
CPT1A mutation in the development of CNS diseases such as MS and depression, 
although the mechanisms are unknown.  
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CHAPTER 2. OBJECTIVES 
The complex interaction between metabolism and immune system described in CNS 
diseases are of outermost importance for identifying mechanisms leading to MS 
thereby finding an effective treatment strategy as there must be aspects of MS 
development, progression and treatment that we still do not understand. The aim of 
the PhD thesis has therefore been to obtain a thorough understanding of the 
metabolism in health and disease using in vivo models of MS and the common 
comorbid condition, depression. 
In order to investigate the overall aim of the PhD thesis four studies with the 
following objectives have been conducted: 
Manuscript I: To investigate the role of the lipid metabolism blocker, etomoxir, in 
rodent EAE models of MS with effects on MBP, CPT1A and FTH expression and 
cytokine production. 
Manuscript II: To investigate the efficacy of the lipid metabolism blocker, etomoxir, 
and the standard treatment of MS, interferon-β, on the autoantibody response in a rat 
EAE model of MS in order to identify potential biomarkers for MS.  
Manuscript III: To investigate the role of a Cpt1a P479L mutation in a mouse EAE 
model of MS with effects on MBP and CPT1A expression as well as on expression 
of genes involved in oxidative stress. Furthermore, the impact of high-fat diet (HFD) 
on the disease course was evaluated.  
Manuscript IV: To investigate the efficacy of the lipid metabolism blocker, etomoxir 
compared to the standard treatment of depression, escitalopram, in a rat CMS model 
of depression. 
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CHAPTER 3. RESULTS 
3.1. MANUSCRIPT I 
Pharmacological inhibition of carnitine palmitoyl transferase 1 inhibits and 
reverses experimental autoimmune encephalomyelitis in rodents 
Anne Skøttrup Mørkholt1, Michal Krystian Oklinski1, Agnete Larsen2, Robert 
Bockermann3, Shohreh Issazedeh-Navikas3, Jette Goller Kloth Nieland4, Tae-Hwan 
Kwon5, Angelique Corthals6, Søren Nielsen1, John Dirk Nieland1 
1Department of Health Science and Technology, Aalborg University, Aalborg, 
Denmark. 2Department of Biomedicine, Aarhus University, Aarhus C, Denmark. 
3Biotech Research and Innovation Centre, Copenhagen University, Copenhagen N, 
Denmark. 4Meta-IQ, ApS, Aarhus C, Denmark. 5Department of Biochemistry and 
Cell Biology, Kyungpook National University, Taegu, Korea. 6Department of 
Science, City University of New York, New York, United States. 
Manuscript submitted 
Abstract 
Multiple sclerosis (MS) is a neurodegenerative disease characterized by 
demyelination and inflammation. Dysregulated lipid metabolism and mitochondrial 
dysfunction are hypothesized to play a key role in MS. Carnitine Palmitoyl 
Transferase 1 (CPT1) is a rate-limiting enzyme for beta-oxidation of fatty acids in 
mitochondria. The therapeutic effect of pharmacological CPT1 inhibition with 
etomoxir was investigated in rodent models of myelin oligodendrocyte glycoprotein- 
and myelin basic protein-induced experimental autoimmune encephalitis (EAE). 
Mice receiving etomoxir showed lower clinical score compared to placebo, however 
this was not significant. Rats receiving etomoxir revealed significantly lower clinical 
score and lower body weight compared to placebo group. When comparing etomoxir 
with interferon-β (IFN-β), IFN-β had no significant therapeutic effects, whereas 
etomoxir treatment starting at day 1 and 5 significantly improved the clinical scores 
compared to the IFN-β and the placebo group. Immunohistochemistry and image 
assessments of brain sections from rats with EAE showed higher myelination 
intensity and decreased expression of CPT1A in etomoxir-treated rats compared to 
placebo group. Moreover, etomoxir mediated increased interleukin-4 production and 
decreased interleukin-17α production in activated T cells. In conclusion, CPT1 is a 
key protein in the pathogenesis of EAE and MS and a crucial therapeutic target for 
the treatment. 
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3.2. MANUSCRIPT II 
Identification of brain antigens recognized by autoantibodies in experimental 
autoimmune encephalomyelitis-induced animals treated with etomoxir or 
interferon-β 
Anne Skøttrup Mørkholt1*, Kenneth Kastaniegaard1*, Michael Sloth Trabjerg1, 
Gopana Gopalasingam1, Wanda Niganze1, Agnete Larsen2, Allan Stensballe1, Søren 
Nielsen1, John Dirk Nieland1 
1Department of Health Science and Technology, Aalborg University, Aalborg, 
Denmark. 2Department of Biomedicine, Aarhus University, Aarhus C, Denmark. 
* = Equal contribution 
Manuscript published in Scientific Reports, 04 May 2018 
Abstract 
Multiple sclerosis (MS) is a neurodegenerative autoimmune disease, where chronic 
inflammation plays an essential role in its pathology. A feature of MS is the 
production of autoantibodies stimulated by an altered-peptide-ligand response and 
epitope spreading, resulting in loss of tolerance for self-proteins. The involvement of 
autoantibodies in MS pathogenesis has been suggested to initiate and drive 
progression of inflammation; however, the etiology of MS remains unknown. The 
effect of etomoxir and interferon-β (IFN-β) was examined in an experimental-
autoimmune-encephalomyelitis (EAE) model of MS. Moreover, the impact of 
etomoxir and IFN-β on recognition of brain proteins in serum from EAE rats was 
examined with the purpose of identifying the autoantibody reactivities involved in 
MS. Animals treated with etomoxir on day 1 exhibited a statistically significantly 
lower disease score than animals treated with IFN-β (on day 1 or 5) or placebo. 
Etomoxir treatment on day 5 resulted in a significantly lower disease score than 
IFN-β treatment on day 1. After disease induction antibodies was induced to a broad 
pallet of antigens in the brain. Surprisingly, by blocking CPT1 and therewith lipid 
metabolism several alterations in the antibody response was observed suggesting 
that autoantibodies play a role in the EAE animal model.  
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3.3. MANUSCRIPT III 
CPT1A plays a key role in the development and treatment of multiple sclerosis 
and experimental autoimmune encephalomyelitis 
Anne Skøttrup Mørkholt1, Michael Sloth Trabjerg1, Michael Krystian Egelund 
Oklinski1, Luise Bolther1, Lona John Kroese2, Colin Eliot Jason Pritchard2, Ivo 
Johan Huijbers2, John Dirk Vestergaard Nieland1 
1Department of Health Science and Technology, Aalborg University, Aalborg, 
Denmark. 2Mouse Clinic for Cancer and Aging, Transgenic Facility, The 
Netherlands Cancer Institute, Amsterdam, The Netherlands. 
Manuscript submitted 
Abstract 
Background: Human mutations in carnitine palmitoyl transferase 1A (CPT1A) are 
correlated with remarkably low prevalence of Multiple Sclerosis (MS) in the Inuits 
(P479L) and Hutterites (G710E). To elucidate the role of CPT1A, we established a 
Cpt1a P479L mouse strain and tested the sensitivity to experimental autoimmune 
encephalomyelitis (EAE). Moreover, we tested the effect of high-fat diet (HFD) on 
disease severity.  
Methods: EAE was induced in C57BL/6J wild type (WT) and Cpt1a P479L mice 
and clinical score and weight were evaluated daily. The protein expression of myelin 
basic protein (MBP) and CPT1A were investigated by immunohistochemistry and 
western blotting, and the gene expression of Cpt1 and markers of oxidative stress 
were investigated by RT-qPCR.  
Results: The disease symptoms progressed and increased significantly throughout 
the experiment in WT mice in contrast to Cpt1 P479L mice. WT mice receiving 
HFD, in contrast to mice receiving normal diet (ND) and Cpt1a P479L mice 
receiving ND or HFD, showed significantly exacerbated disease course. After the 
EAE induction, the expression of MBP was significantly reduced in the WT mice 
compared to the Cpt1a P479L mice. The expression of Cpt1c was significantly 
increased in Cpt1a P479L mice compared to WT mice. The WT mice showed 
significantly increased expression of Ho-1 compared to CPT1a mice, whereas the 
expression of Pgc1α was increased in Cpt1a P479L mice.  
Conclusion: In conclusion, these findings support a key role of CPT1A and lipid 
metabolism in the development of MS and could be a promising pharmacological 
target in the treatment of MS.  
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3.4. MANUSCRIPT IV 
Blocking of carnitine palmitoyl transferase 1 potently reduces stress-induced 
depression in rat highlighting a pivotal role of lipid metabolism 
Anne Skøttrup Mørkholt1, Ove Wiborg2, Jette Goller Kloth Nieland3, Søren 
Nielsen1, John Dirk Nieland1 
1Department of Health Science and Technology, Aalborg University, Aalborg, 
Denmark. 2Department of Clinical Medicine, Aarhus University, Risskov, Denmark. 
3 Meta-IQ, ApS, Aarhus C, Denmark. 
Manuscript published in Scientific Reports, 19 May 2017 
Abstract 
Major depressive disorder is a complex and common mental disease, for which the 
pathology has not been elucidated. The purpose of this study is to provide 
knowledge about the importance of mitochondrial dysfunction, dysregulated lipid 
metabolism and inflammation. Mitochondrial carnitine palmitoyl transferase 1A 
(CPT1A) is a key molecule involved in lipid metabolism and mutations in CPT1A 
causing reduced function is hypothesized to have a protective role in the 
development of depression. Moreover, CPT1A is found to be upregulated in suicide 
patients with history of depression. Therefore, we hypothesized that inhibition of 
CPT1A activity can be developed as an innovative treatment strategy for depression. 
Stress exposure combined with different pharmacological treatment regimens; 
Etomoxir, CPT1 blocker, and Escitalopram, a favored antidepressant drug, was 
applied in state-of-the art chronic mild stress model. Etomoxir treatment induced 
statistical significant reduction of anhedonic behavior compared to vehicle treatment 
(p<0.0001) and reversed depression-like phenotype in 90 % of the rats (p=0.0007), 
whereas Escitalopram only proved 57 % efficacy. Moreover, Etomoxir revealed 
downregulation of interferon-γ, interleukin-17α and tumor necrosis factor-α. This 
indicate that alteration in metabolism is pivotal in the pathogenesis of depression, 
since CPT1 blockage is highly efficient in treating anhedonia and inflammation, 
thereby opening up for a novel class of antidepressant medication.  
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CHAPTER 4. DISCUSSION 
The objective of the PhD thesis was to obtain an understanding of the role of the 
metabolism in CNS in health and disease using in vivo animal models of MS and 
depression. The aim with this approach was to come a step closer in clarifying the 
etiology, development, progression and treatment opportunities of these as well as 
other CNS diseases. Based on the experimental studies presented in Manuscript I-IV 
and findings of the literature this chapter is a combined discussion of all the projects 
with metabolism as the central part. 
4.1. THE TRADITIONAL AND SYSTEMIC FRAMEWORK OF 
MULTIPLE SCLEROSIS 
The traditional way of understanding the etiology and pathology of MS is as an 
inflammatory autoimmune disease of the CNS, thus interpreting it as an isolated 
disease referred to as the traditional framework. However, it has become evident that 
more complex systems underlie the etiology and pathology of MS, therewith 
constituting the systemic framework. Both of these frameworks will be discussed in 
the following paragraphs. 
4.1.1. THE TRADITIONAL FRAMEWORK 
For a long time MS has been regarded as an inflammatory autoimmune disease 
influenced by immunological, genetic and environmental pathologic factors, which 
constitutes the basis of the traditional framework. 
This traditional framework covering the immunological part is initiated by exposure 
to a brain infection or a peripheral infection of an individual, which stimulates the 
activation of autoreactive T cells in the CNS directly or by mechanisms like for 
example molecular mimicry, altered peptide ligand or bystander activation (11,12). 
The T cells recognize CNS antigens and initiate an inflammatory autoimmune 
response. This response is thought to be the trigger of MS development which is 
further characterized by the pathological hallmarks such as breakdown of the BBB, 
demyelination and axonal degeneration (11). According to this framework, the 
reversible disability seen in RRMS is a result of focal regions of inflammatory 
demyelination where the oligodendrocytes, the myelin and the axons are destroyed. 
When monocytes and lymphocytes cross the BBB and enter the CNS, the lesions 
become edematous and the inflammation can be attributed to this process. After this 
the onset of neurological decline occurs rapidly and the dysfunction of axons is a 
result of blocked nerve conduction due to the edema and serum components. The 
remission phase covers decreased inflammation along with remyelination and 
therewith restoration of axonal conduction followed by relapses and after years, 
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patients enter SPMS with no relapses. The transition from RRMS to SPMS is 
assigned to the progressive loss of axons (3).  
Genetic and environmental risk factors of MS influence the function of the immune 
system. MS has been considered as a disease with an inherited risk for disease 
susceptibility (3). The risk for MS is increased if you have an affected parent. The 
HLA-DRB1 gene is the dominant MS-associated gene accounting for 16-60 % of the 
genetic susceptibility however this association has not been confirmed for MS 
patients in general (81,146). Women are also affected more often than men in a 2:1 
ratio (9). Furthermore, the MS incidence is increased in Europeans compared to 
American Indians, Africans and Asians (147). Environmental factors such as 
microbial infections are also thought as an important trigger of MS by molecular 
mimicry where T cells recognize an epitope from an infectious agent cross-reacting 
with a self-antigen. An association between relapses and recent viral or bacterial 
infections are found, though no specific infectious agent has been identified (148). 
Moreover, vitamin D has been found to regulate the immune system as well as 
decreasing the MS incidence (149). These external factors have proved elusive, 
since exposure of infectious agents in similar populations have different disease 
incidence and populations obtaining high vitamin D levels have high disease 
incidence (81).  
Until today the immunologic factors have been the logical explanation for the 
disease development and also the basis for the development of therapies for the 
treatment of MS. However, other pathologic findings present in MS can neither be 
explained by focusing solely on the traditional framework. These findings include 
disease progression from RRMS to PPMS and SPMS, since the inflammation peaks 
at the time of RRMS, whereas loss of brain volume decreases and axonal loss 
increases. While transitioning to SPMS, inflammation decreases along with a rapidly 
increase in loss of brain volume and axonal loss (11). Moreover, the current disease-
modifying therapies functioning by slowing down the inflammation have only 
shown efficacy in RRMS though remaining limited to symptomatic relief and have 
shown no effect in PPMS and SPMS (1,4). Nevertheless these therapies are not able 
to stop the progressive neurological decline contributing to disability. Other 
uncovered findings in the pathology include changes in lipid levels marked by 
reduced PUFA levels in particular palmitate and oleate lipids (150). Iron 
accumulation where iron is released from demyelinating lesions contributing to 
oxidative stress. Glutamate excitotoxicity leading to calcium influx into neurons, 
which results in neurodegeneration. Microglial production of pro-inflammatory 
cytokines, ROS and RNS are toxic for neurons and oligodendrocytes thus promoting 
mitochondrial dysfunction and oxidative stress (4). Mitochondrial dysfunction 
demonstrated by reduced numbers of mitochondria and energy production 
contributing to calcium-mediated axonal degeneration. Activation of mitochondrial 
permeability pores leads to mitochondrial swelling, rupture of membrane and release 
of apoptotic mediators (98). 
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Since this traditional framework is incomplete in clarifying the etiology of MS and 
too simple for explaining the development, progression along with the inefficient 
treatment therapies, this opens up for a new framework for MS. This is an attempt to 
clarify the etiology and pathology of MS by covering all aspects with the goal of 
developing a therapy stopping and preventing the progression of MS. 
4.1.2. THE SYSTEMIC FRAMEWORK 
It has been evident that more complex systems underlie the pathology of MS, which 
opens up a new systemic framework challenging the current traditional one. In 
contrast to the traditional framework, all the well-demonstrated pathological 
hallmarks characterized in MS are covered by this systemic model, where a shift in 
metabolism plays a central role. Altered metabolism is therefore suggested to play 
an essential role in the pathogenesis of MS with lipids as a denominator, since the 
lipid metabolism affects several cellular mechanisms. Even though the immune 
system plays a more prominent role in RRMS than in PPMS and SPMS, most of the 
processes described are out of balance. 
The knowledge of disturbed glucose metabolism in the pathology of MS are limited, 
however much literature hints to a link. The weight of the brain represents 2 % of 
the total body weight, though 25 % of the total body glucose is utilized by it, which 
underpins the importance of a continuous glucose supply making it the main energy 
source in the brain (151). The importance of lipids is proven by the fact that lipids 
represent the dry weight of 33 % in the grey matter, 55 % in the white matter and 70 
% in myelin (152). The lipids are produced by the oligodendrocytes, which are able 
to produce up to 50 or more segments of myelin (114). This extraordinary high 
demand for lipids is essential to form myelin sheath for wrapping and insulating 
axons, thus propagating efficient neuronal impulses. This dependence on lipids is 
highlighted by pathologies disturbing myelination, such as MS, which affects lipid 
metabolism (153).  
The systemic model is the basis of a new conceptual framework of the pathologic 
findings in MS (Figure 2). Stimuli such as stress are a broad term which could be 
induced by physiological, psychological and pathological (viral, bacterial, or fungal 
infection) factors. Stress affects all the mechanisms proposed, which are connected 
directly or indirectly to each other and initiates a cascade of events. Therefore it has 
to be interpreted as complex network with shift in metabolism as the central part. 
Stress induces shift in metabolic pathways from glucose-based to lipid-based 
metabolism. The transcriptional regulators, PPARs, serve as a link between energy 
balance, lipid homeostasis and immune system by sensing lipid levels. Due to 
increased lipid metabolism, the expression of PPARs is decreased. This results in 
dysregulation of PPARs promoting disinhibition of inflammatory response proteins, 
oxidative stress and myelin degradation (81). 
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Inflammation induced by the increased lipid metabolism causes increased activity of 
CPT1 transporting long-chain fatty acids, which stimulates pathogenic T cell (Th1 
and Th17 cells) differentiation (125). An acute inflammatory response promotes 
shift from storage of lipids to sequestration of lipids by immune cells. Favoring lipid 
metabolism also promotes imbalance in cytotoxic and phagocytic microglia and T 
cells resulting in chronic activated cytotoxic cells, which lack self-regulatory 
apoptotic mechanisms inducing neurodegeneration (81). 
Activation of the HPA axis affects the CNS and the gut, which causes release of 
glucocorticoids, mineralocorticoids and catecholamines resulting in altered gut 
microbiota composition, increased gut permeability and increased immune response 
(102). Cytokines are able to regulate the HPA axis leading to impairment of the 
negative feedback mechanism, which is mediated by the hippocampus, thus 
resulting in overproduction of glucocorticoids (48). Chronic stress causes increased 
cortisol secretion thus limiting the inhibitory effect of cortisol on the immune 
response. Due to these high levels of glucocorticoids, macrophages and microglia 
release pro-inflammatory cytokines. Consequently, this leads to loss of 
glucocorticoid receptors disinhibiting the HPA axis (40,50). This produces 
neurotoxic free radicals and decreased glucose transport (40) leading to oxidative 
stress and insulin resistance, thus entering the vicious cycle.  
Oxidative stress could be caused by hypoxia imposing stress to cells, which is a 
process linked to inflammation. The metabolism is altered in attempt to adapt to the 
lack of oxygen. This is facilitated by changes in expression of proteins, which 
stabilizes the transcription factor hypoxia inducible factor. Hypoxia alters oxidative 
phosphorylation, which is adapted to hypoxia by remodeling the electron transport 
chain and the Krebs cycle. Changes in the composition of electron transport chain 
complexes increases the production of ROS, which oxidizes proteins associated with 
the Krebs cycle as pyruvate dehydrogenase, for example (154). It can also be caused 
by ischemia, where influx of calcium together with increased levels of ROS and 
RNS stimulate opening of the mitochondrial permeability transition pores. 
Consequently, this leads to mitochondrial dysfunction characterized by influx of 
solutes, loss of the mitochondrial membrane potential and equilibrium of ion 
gradients. This prevents synthesis of ATP and causes expansion of the mitochondrial 
matrix, swelling and rupture of the mitochondria membrane with resulting cell death 
(154,155).  
To accomplish the production of the massive quantities of lipids necessary for 
myelination, enzymes are required. The high levels of iron in the oligodendrocytes 
could be due to the required enzymes involved in the highly metabolic process when 
producing myelin (114). However, in neurons and oligodendrocytes the 
mitochondria are possible areas of iron deposits leading to accumulation of iron 
(114). Ferrous iron in the presence of hydrogen peroxide generates ROS, which 
further stimulates oxidative stress (112,156).  
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Figure 2. The systemic model. Description of the systemic model characterized by a complex 
network with shift in metabolism favoring lipid metabolism instead of glucose metabolism as 
the central part. Dysregulated metabolism is connected to several pathologic mechanisms 
inflammation, hyperactivation of HPA axis, oxidative stress, mitochondrial dysfunction, iron 
accumulation, demyelination, BBB breakdown and dysbiosis of microbiota. BBB: blood-brain 
barrier, HPA: hypothalamic-pituitary-adrenal axis, PPARs: peroxisome proliferator-
activated receptors.  
Myelination requires high demand of lipids. The myelin membrane contains high 
levels of cholesterol, thus dependent on the cholesterol synthesis. Defects in the 
metabolism of myelin-enriched lipids, such as cholesterol and long-chain fatty acids, 
cause demyelination (157). Moreover, lipids become targets for lipid peroxidation, 
and post-translational modifications such as citrullination modifying arginine to 
citrulline, which is involved in MBP. This delipidation leads to recognition of 
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citrulline-modified MBP antigens by the immune cells in the CNS and thus altered 
peptide ligand causes inflammation as well as autoimmunity (14).  
The BBB is compromised due to high levels of circulating fatty acids causing 
deficient expression PPARs, which regulates the integrity of the BBB. This results 
in monocytes entering the CNS further stimulating inflammation (81,158). Damage 
to the BBB causes leakage of transferrin-bound iron, which increases the iron 
content in the CNS making it more prone to mitochondrial dysfunction and 
oxidative stress (112).  
Insulin resistance is a result of increased lipid metabolism followed by production of 
increased amounts of acetyl-CoA that inhibits pyruvate dehydrogenase. This 
elevates the levels of glucose-6-phospaphate and inhibits hexokinase contributing to 
insulin resistance. Additionally, fatty acids can inhibit glycogen synthesis through 
GLUT4 causing insulin resistance (120). Thereby, the brain is forced to use lipids as 
energy substrate due to the reduced influx of glucose. 
All these mechanisms underpin a central role of lipid metabolism in MS and during 
conditions of dysregulated lipid metabolism a vicious cycle where several 
pathologic processes will be initiated (Figure 2). Despite of which event is the 
trigger of these processes, the initiating event will affect all the other mechanisms 
involved. For example intake of diet high in triglycerides promotes inflammation, 
persistent exposure to stress promotes activation of the HPA axis and smoking 
causes changes in the microbiota. Common for the all these initiators (diet, stress, 
smoking) is that they start the cascade of pathological processes leading to disease. 
This clear cut function of the metabolism of lipids together with the importance of 
lipids for the brain function underpin that the lipid metabolism and thus CPT1 plays 
a central role in the etiology and pathology of MS, which are supported by the 
research presented in Manuscript I-III. 
4.1.3. RESEARCH CONFIRMING THE SYSTEMIC FRAMEWORK 
Manuscript I-III covers research supporting the systemic framework proposed as an 
explanation of the etiology and pathology of MS. Detailed results are described in 
the manuscripts (Appendix A-C) (14).  
Manuscript I is comparing the traditional and systemic framework by testing the 
efficacy of the standard immunotherapy of MS, interferon-β, and the lipid 
metabolism blocker, etomoxir. It covers an attempt to reverse EAE in rodents 
obtained through the mechanism of action of etomoxir blocking the lipid 
metabolism by targeting CPT1 resulting in downregulation of β-oxidation. The EAE 
model showed significantly increased mean clinical score and decreased body 
weight in placebo-treated animals compared to etomoxir-treated animals, which 
indicates amelioration of disease. The new therapy, etomoxir, was compared to the 
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first-line treatment of MS, interferon-β, showing significantly superior effects to 
interferon-β treatment in the animals. The treatment strategy with both etomoxir and 
interferon-β was evaluated by investigating the effects of the treatments initiated at 
different time points, day 1 or day 5. Treatment with etomoxir initiated at day 1 
showed increased efficacy compared to day 5. This indicates that etomoxir treatment 
day 1 revealed a prompt response relevant for the clinical application of etomoxir 
consistent with findings by Shriver et al. who found beneficial effect of etomoxir 
treatment (131). In addition, the unsuccessful inhibition of disease by interferon-β 
underpin that this treatment is not covering all aspects since the animals did not 
reverse the EAE-induced symptoms.  
The effect of etomoxir was evaluated by the protein expression of CPT1A, MBP and 
FTH in the brain (brainstem and cerebellum). The intensity of CPT1A was 
significantly lower in etomoxir-treated animals compared to placebo-treated animals 
confirming the therapeutic efficacy of etomoxir treatment by downregulating the 
lipid metabolism. This indicates that the metabolism is reversed from increased lipid 
metabolism in the EAE-diseased animals to mainly relying on glucose metabolism, 
which is important to sustain physiological brain function. In accordance, the MBP 
intensity was significantly increased in the cerebellum after etomoxir treatment 
compared to animals receiving placebo. By the increased MBP levels in the 
brainstem was also low occurrence of immune infiltrates. This supports the 
hypothesis of reversed metabolism favoring glucose metabolism by etomoxir, which 
promotes improved myelination along with low mean clinical scores.  
The oligodendrocytes produces lipids incorporated into myelin and this process 
requires sufficient energy and some of these processes utilize iron (114). However, 
excessive amounts of redox-active iron are proposed as a generator of ROS in MS 
and EAE via Fenton reactions facilitating reduction of hydrogen peroxide to highly 
toxic hydroxyl radicals (156). The FT levels are increased in EAE animals compared 
to controls (159). Upregulated expression of FT in EAE and MS is associated with 
protection against oxidative damage in cells and inhibition of inflammation 
(114,159). This was supported by the findings of reduced FTH expression in the 
brain after etomoxir treatment. In contrast, the placebo group showed higher FTH 
expression, which may be due to a protective mechanism limiting the damaging 
effects of iron. With increased iron load in the cells follows downregulation of 
transferrin along with upregulation of FT as protection against the toxic iron by 
restricting the entry of additional iron and binding and storage of released iron, 
respectively (160). This underpin that etomoxir is functioning by reversing 
mitochondrial dysfunction demonstrated by data of FTH expression, which 
illustrates iron deposits. In summary, the experimental data in Manuscript I support 
the hypothesis regarding MS as a systemic disease with lipid metabolism considered 
as a new target apart from solely inflammation, which has been the focus until 
today.  
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Manuscript II covers another new framework for the pathogenesis of MS involving 
B cells and autoantibodies in MS, thought to play a central role due to the 
correlation between disease progression and oligoclonal bands. This study was an 
attempt to investigate the antibody-antigen response in EAE and the efficacy of 
treatment with etomoxir and interferon-β hereof in order to identify autoantigens and 
potential biomarkers (14).  
The EAE model is associated with inflammation, which was supported by the 
findings of significantly increased autoantibody reactivity to positive acute phase 
reactants as α-1-acid glycoprotein, haptoglobin, ceruloplasmin and plasma protease 
C1 inhibitor, as well as decreased autoantibody reactivity to negative acute phase 
reactants as transthyretin and α1-inhibitor-3 in the placebo group compared to the 
control group. These results were consistent with the increased clinical scores 
presented in the placebo animals, which implies high levels of positive acute phase 
reactants and low levels of negative acute phase reactants in EAE. Acute phase 
proteins are synthesized by the liver and released systemically in response to 
stressful stimuli. The expression of these acute phase proteins is regulated by pro-
inflammatory cytokines such as IL-1, IL-6 and TNF-α (161). 
Several significant differences in the reactivity of autoantibodies to antigens were 
demonstrated between the treatment groups (etomoxir day 1 or day 5, or interferon-β 
day 1 or day 5) and the placebo and control group. The relative autoantibody 
reactivity to APOE, clusterin, plasma protease C1 inhibitor and serum amyloid P 
component were among others decreased in animals treated with etomoxir, whereas 
serum albumin was increased compared to the placebo group. The levels of relative 
autoantibody reactivity to complement component C9 and gelsolin were among 
others decreased in animals treated with interferon-β compared to animals receiving 
placebo. The APOE gene is associated with MS (162). APOE is important for the 
transport, uptake and distribution of cholesterol, which is essential for repair of 
nerve tissue proposing a critical role for lipid metabolism. Moreover, APOE is 
important for modification of inflammatory responses in brain and regulation of the 
BBB integrity and function (162,163). All mechanisms important for restoring CNS 
function during relapses. The increased reactivity to APOE in animals receiving 
placebo compared to etomoxir-treated animals reveals neuroinflammation in the 
CNS, which was also demonstrated by Shin et al., who showed infiltrates with 
dendritic cells expressing high levels of APOE in the CNS of EAE animals (163). In 
summary, the experimental data in Manuscript II demonstrates significant changes 
in the serum antibodies against several proteins suggesting a significant role of B 
cells in the pathogenesis of MS. Further supporting an important role of B cells is 
the efficacy of Ocrelizumab, which is a humanized monoclonal antibody that 
depletes CD20-expressing B cells. It has shown lower rates of disease progression in 
RRMS and PPMS compared to placebo (16,17). Continuing with this framework 
and arranging the autoantigens detected, more than 30 autoantigens were modulated 
after treatment with etomoxir, where around half of them were involved in 
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metabolic processes and the other half was involved in stress. This demonstrates that 
alteration in the metabolic pathways is essential in MS pathogenesis and 
identification of such autoantibodies against brain antigens opens up for recognition 
of potential biomarkers for MS. 
Until now the experimental data demonstrates that pharmacological inhibition of 
CPT1 revealed clinical efficacy in the EAE models, effects on the T cell response by 
downregulating inflammation and effects on the B cell response by downregulating 
autoantibodies involved in inflammatory processes and metabolic pathways. 
Overall, this supports the hypothesis of the central role of lipid metabolism and in 
particular CPT1 suggesting a new systemic treatment strategy in MS affecting 
metabolism, inflammation, oxidative stress and mitochondrial dysfunction rather 
than focusing solely on either T cells or B cells. 
In order to confirm that lipid metabolism plays a central role in MS, we have 
generated mice with a Cpt1a P479L mutation mimicking the Inuit mutation. It can 
be speculated whether the findings of low MS prevalence in the Inuit population is a 
consequence of decreased lipid metabolism due to the Cpt1a P479L mutation or 
because of other risk factors, such as diet, environment or genetics. Studies to test 
this are covered in Manuscript III by the unique use of Cpt1a P479L mice, which 
are hypothesized to be resistant to development of MS, based on the Inuit data and 
the proposed systemic framework. In the EAE model, significant lower mean 
clinical score and increased body weight were demonstrated in Cpt1a P479L EAE 
mice compared to wild type (WT) EAE mice supporting the proposed hypothesis of 
resistance to develop EAE (and MS in humans) obtained by the Cpt1a P479L (and 
CPT1A P479L) mutation. 
The low prevalence of MS in Canadian and Greenland Inuits is a result of a 
metabolism where glucose is favored as energy substrate due to the low residual 
enzymatic activity of CPT1A thereby forcing glucose-based metabolism instead of 
lipid-based metabolism. Furthermore, the traditional Inuit diet consists of animal-
based diet rich in proteins and vitamins. This caloric restricted intake is associated 
with decreased inflammation, as it is demonstrated that HFD modulates PPARs and 
induces brain inflammation and oxidative stress, and is associated with increased 
MS frequency. This underpin that fatty acids are important modulators of 
inflammation and energy homeostasis (164,165). In order to clarify the role of diet 
in the Inuits and Cpt1a P479L mice, the influence of HFD on disease severity was 
investigated. It was found that WT EAE mice receiving HFD compared to normal 
diet (ND) showed exacerbated disease course, which was in accordance to other 
studies (164). To support the proposed hypothesis of resistance, the effect of HFD 
was tested. The data showed that diet was not a trigger to exacerbated EAE disease 
course in Cpt1a P479L EAE mice as the mean clinical score was not affected. In 
addition, Cpt1a P479L EAE mice receiving ND and HFD showed significantly 
lower mean clinical score compared to WT mice receiving HFD.  
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Excess levels of ROS are mediators of demyelination and axonal damage in EAE 
and MS, since ROS causes damage to lipids (111). HO-1 is increased in the CNS of 
EAE mice and in MS lesions (159). The upregulation of HO-1 is induced by ROS 
activating Nrf2. The increase in Ho-1 mRNA expression in WT mice compared to 
Cpt1a P479L EAE mice proposes the presence of oxidative stress in WT mice. A 
regulator of mitochondrial antioxidants in MS, Pgc1α (166), was increased in Cpt1a 
P479L EAE mice compared to WT mice indicating a defense mechanism in Cpt1a 
P479L EAE mice by restoring the redox balance. This finding supports the 
hypothesis that antioxidant pathways protect neurons from inflammatory-mediated 
oxidative stress in the EAE model and that Cpt1a P479L mice possess antioxidant 
properties, which is another framework for describing the resistance to EAE 
development. The resistance to EAE development for Cpt1a P479L mice is 
consistent with the low prevalence of MS in the Inuit population carrying the 
CPT1A P479L mutation. Due to this mutation it is assumed that the metabolism has 
a preference for utilizing glucose compared to individuals with WT CPT1A gene 
with normal prevalence of MS in which the metabolism favors lipids as energy 
substrate.  
The effect of Cpt1a P479L mutation on the protein expression of MBP was 
evaluated in the brain by fluorescent immunohistochemical staining and 
immunoblotting. Cpt1a P479L EAE mice showed markedly increased MBP-labeling 
with no evident pathological lesions in cerebellum and brainstem compared to WT 
EAE mice. These observations were confirmed by quantification of the labeling 
intensity, which demonstrated significant increased values of the integrated density 
of MBP in both brainstem and cerebellum of Cpt1a P479L EAE mice compared to 
WT EAE mice. This confirms improved myelination in Cpt1a P479L EAE mice and 
corresponds to the lower mean clinical scores in these mice. In summary, the 
experimental data in Manuscript III underpin a pivotal role of CPT1A in the 
pathogenesis of MS.   
By the findings presented in Manuscript I-III new treatment avenues of MS through 
a systemic approach targeting lipid metabolism could be proposed, since both 
pharmacological and genetic inhibition of CPT1 and Cpt1a were demonstrated to 
attenuate disease. This is in contrast to the current therapeutic approaches, which 
only treats the collection of symptoms in RRMS and causes relief of these instead of 
hindering disease disability and progression.  
4.2. CENTRAL NERVOUS SYSTEM DISEASES IN THE LIGHT OF 
THE SYSTEMIC FRAMEWORK 
The new conceptual framework sheds new light on the etiology and pathology of 
MS. By using the metabolism of lipids as the etiology of MS rather than the immune 
system factors that previously could not be understood within the strict 
autoimmunity framework can now be explained. It is well-known that depression is 
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comorbidity to MS. Furthermore other CNS diseases such as amyotrophic lateral 
sclerosis, Parkinson´s disease and Alzheimer´s disease have shared features to MS. 
Therefore, it is now interesting to see if the proposed systemic framework can 
explain connections between as well as the etiology and pathology of depression and 
CNS diseases with MS. 
4.2.1. DEPRESSION 
Depression is associated with MS and other CNS diseases, where depression is the 
most common psychiatric disorder in MS patients. The established hypotheses of 
depression including the monoamine, the neutrophin and the cytokine hypothesis 
may still be partly operative, though incomplete in explaining the entire etiology and 
pathology. Inflammation results from decreased availability of neurotransmitters, 
decreased levels of neurotrophic factors, and increased levels of pro-inflammatory 
cytokines. Correspondingly, the traditional framework of MS remains elusive in 
explaining the comorbidity, depression, both of which are multifactorial diseases 
and can be associated with psychosocial stress, inflammation and demyelination 
(98). Thus it is tempting to hypothesize that depression could be explained by the 
systemic framework. 
It is known that in depression the reverse cholesterol transport is impaired due to 
low levels of HDL, total cholesterol and HDL:cholesterol ratio (126). Moreover, 
depletion of PUFAs is associated with increased production of pro-inflammatory 
cytokines such as prostaglandin E2, IL-1, IL-6, TNF-α and interferon-γ, thus 
promoting inflammation and stress. 
Similar to MS, stress induced by internal or external factors is thought to be a trigger 
in genetically susceptible individuals. Stress induces shift in metabolic pathways 
from glucose-based to lipid-based metabolism, where dysregulated lipid metabolism 
plays a central role initiating a cascade of disease-inducing processes (Figure 2). As 
described in the systemic model, which should now encompass depression, 
cytokines activate the HPA axis. The loss of negative feedback mechanism of the 
HPA axis results in increased glucocorticoid and cortisol production (51). In 
addition, as described in more detail in the systemic model of MS, this will again 
affect other mechanisms for example altered microbiota, oxidative stress, 
mitochondrial dysfunction, with dysregulated lipid metabolism playing a central 
role.  
Manuscript IV covers an explanation of depression based on the systemic 
framework by connecting dysregulated lipid metabolism to the uncovered 
mechanisms in the pathology. Detailed results are described in the manuscript 
(Appendix D) (55). This study was an attempt to investigate the role of lipid 
metabolism and the efficacy of treatment with etomoxir in relative to standard 
treatment escitalopram in a CMS model of depression. 
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The CMS rats receiving etomoxir demonstrated significantly increased intake of 
sucrose solution, illustrating hedonic behavior, in week 4 and 5 compared to rats 
receiving escitalopram. Further supporting the efficacy of etomoxir is the levels of 
sucrose intake, which were similar to that of unchallenged rats receiving vehicle. 
The responding rate to etomoxir and escitalopram was measured and showed a 
response rate of 90 % and 57 %, respectively. This is in accordance with the 
response rate of the standard treatments today, which are up to 60 %, thus it 
underpins the relevance of this comparison (61,64). These results indicate that 
etomoxir and thereby blockage of lipid metabolism is able to reverse the stress-
induced anhedonic behavior in a superior manner compared to escitalopram 
functioning in a dramatically different way. Normally, a disadvantage of the 
conventional antidepressants is the slow onset of antidepressant action. However, 
etomoxir shows a response rate of 70 % after one week of treatment.  
Furthermore, results demonstrated significant upregulated expression of CPT1A 
mRNA in the cerebellum of people with history of depression compared to healthy 
controls. This supports the hypothesis with lipid metabolism and CPT1A playing a 
key role in the pathogenesis of depression explained by the systemic framework. 
This means that depression as comorbidity to MS could be explained by the same 
model, why it is now tempting to hypothesize that other comorbidities to MS or 
diseases demonstrating similar features could be explained by this as well. 
4.2.2. AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON´S AND 
ALZHEIMER´S DISEASE  
Metabolic disturbances are thought to play a possible role in the energy homeostasis 
of the CNS and found to be implicated in neurodegenerative diseases such as 
amyotrophic lateral sclerosis, Parkinson´s and Alzheimer´s disease (151). Therefore, 
it is tempting to hypothesize that dysfunction of lipid metabolism is also playing a 
central role in these diseases, since these have common features to MS. 
In amyotrophic lateral sclerosis, a switch from glucose metabolism to lipid 
metabolism has been defined as an early pathologic event prior to detectable motor 
and clinical symptoms (167). Patients with sporadic amyotrophic lateral sclerosis 
have increased levels of circulating fatty acids (168). This prolonged utilization of 
lipids as energy substrate increases β-oxidation leading to production of lipid by-
products that contribute to lipotoxicity and ROS production. Studies have proposed 
that the metabolic switch is caused by increased expression of PPARs (167). 
Restoration of the metabolic balance favoring glucose metabolism is able to protect 
the mitochondria by preventing oxidative stress (167). Familial cases of 
amyotrophic lateral sclerosis are often due to mutation in the cytosolic copper-zinc 
superoxide dismutase 1 gene. Cytosolic copper-zinc superoxide dismutase is an 
enzyme present in the cytosol and mitochondrial intermembrane space, which 
catalyzes removal of superoxide radicals (169). In cytosolic copper-zinc superoxide 
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dismutase 1 mutated mice reduced levels of circulating triglycerides and insulin as 
well as increased levels of glucagon was demonstrated indicating altered lipid 
metabolism (170). These can trigger acidosis, which is thought to catalyze onset and 
progression of amyotrophic lateral sclerosis and other diseases such as MS and 
Parkinson´s disease by activation of acid-sensing ion channels promoting 
intracellular calcium influx, inflammation, demyelination, axonal degeneration and 
neuronal death (170,171). 
In Parkinson´s disease, dysregulation of the fatty acid metabolism have been 
demonstrated (172,173). The reduced level of glucose is deleterious to neurons as it 
results in oxidative stress important for the formation of Lewy bodies (173). 
Additionally, it causes increased activation of microglia which is associated with 
neuronal damage (174).  
In Alzheimer´s disease, APOE is the strongest genetic risk factor and serves as a 
regulator of the cholesterol metabolism in the brain by transporting HDL particles. 
There has been found increased levels of low-density lipoprotein and decreased 
levels of HDL (175). In Alzheimer´s disease a decline in glucose metabolism of 
brain has been demonstrated (176). This compromised metabolism is accompanied 
with oxidative stress, which causes degradation of myelin. Free cholesterol 
contributes to overproduction of amyloid-β, which will accumulate in the 
mitochondria further perpetuating oxidation of fatty acids favoring lipid metabolism 
(176).  
The findings in amyotrophic lateral sclerosis, Parkinson´s and Alzheimer´s disease 
demonstrate dysfunction of lipid metabolism and features which can be described by 
the systemic framework as proposed for MS. Therefore, it may be assumed that 
inhibition of lipid metabolism by targeting CPT1A could be efficient as treatment 
strategy for these diseases as well.  
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CHAPTER 5. CONCLUSION 
The traditional framework of the etiology and pathology of MS as an inflammatory 
autoimmune disease of the CNS is elusive in both explaining the disease and 
generation of efficient therapies. Therefore, more complex mechanisms underlie the 
understanding of the etiology and pathology of MS, which is proposed as the 
systemic framework. This systemic model constituted the major focus of this PhD 
thesis hypothesizing that MS and depression originate from a dysfunction of the 
metabolism of lipids. Without a clear understanding of the etiology and pathology 
the hope for a cure is limited. Therefore, the open question is: does a change of 
paradigm in which MS and depression are seen as systemic diseases generate 
treatments of these diseases with metabolic pathways as the central part?  
The results presented throughout the PhD thesis provide convincing evidence of this 
new framework. Etomoxir treatment promotes the use of glucose as preferred energy 
substrate instead of lipids, thus preventing disease development. This was 
demonstrated by efficient blockage of lipid metabolism in mice and rats exposed to 
EAE resulting in ameliorated clinical scores and remyelination. Etomoxir showed 
superior efficacy to interferon-β treatment, targeting T cell function, as well 
modification of the antibody response, targeting B cell function. Moreover, etomoxir 
was able to reduce the levels of pro-inflammatory cytokines. This proposes multiple 
functions involved in the pathogenesis, which are affected by etomoxir treatment. 
The results were further supported by the findings of resistance to disease by the 
Cpt1a P479L or arctic mutation as well as resistance to exacerbated disease severity 
by HFD. Blockage of lipid metabolism by etomoxir was also efficient in treating rats 
exposed to CMS by reducing the anhedonic behavior compared to escitalopram.  
In conclusion, the research presented in Manuscript I-IV in this PhD thesis 
exemplifies the complexity of diseases such as MS and depression, which has 
important implications for the development of new therapeutic approaches. The 
results have provided new insight into MS and depression by proposing a central 
role of CPT1A in systemic treatment of these diseases, which indicates a change of 
paradigm towards therapies focusing on CPT1A as the target on a pathway to a new 
cure. 
5.1. FUTURE PERSPECTIVES  
This PhD thesis provides a framework for further investigations of the lipid 
metabolism and in particular the CPT1A molecule in CNS diseases due to the need 
of efficient treatment opportunities helping individuals for which there is no cure 
today. The first step is to implicate dysfunction of lipid metabolism in the etiology 
of MS and understand the systemic framework of the disease, instead of solely 
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focusing on the immune system. The second step is to evaluate the clinical efficacy 
of etomoxir in order to aid our understanding of the pathogenesis and progression of 
MS, which could allow health organizations and health care professionals to better 
predict the onset of disease in individual patients by monitoring risk factors 
including clinical history and environmental triggers. Additionally, revisiting the 
processes of MS in this framework could also improve the current problematic 
ability to diagnose MS. Overall this systemic framework has opened new and 
exciting avenues for the development of potential novel therapeutics for CNS 
diseases.  
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Identification of brain antigens 
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encephalomyelitis-induced 
animals treated with etomoxir or 
interferon-β
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Multiple sclerosis (MS) is a neurodegenerative autoimmune disease, where chronic inflammation plays 
an essential role in its pathology. A feature of MS is the production of autoantibodies stimulated by an 
altered-peptide-ligand response and epitope spreading, resulting in loss of tolerance for self-proteins. 
The involvement of autoantibodies in MS pathogenesis has been suggested to initiate and drive 
progression of inflammation; however, the etiology of MS remains unknown. The effect of etomoxir 
and interferon-β (IFN-β) was examined in an experimental-autoimmune-encephalomyelitis (EAE) 
model of MS. Moreover, the impact of etomoxir and IFN-β on recognition of brain proteins in serum 
from EAE rats was examined with the purpose of identifying the autoantibody reactivities involved in 
MS. Animals treated with etomoxir on day 1 exhibited a statistically significantly lower disease score 
than animals treated with IFN-β (on day 1 or 5) or placebo. Etomoxir treatment on day 5 resulted in a 
significantly lower disease score than IFN-β treatment on day 1. After disease induction antibodies was 
induced to a broad pallet of antigens in the brain. Surprisingly, by blocking CPT1 and therewith lipid 
metabolism several alterations in the antibody response was observed suggesting that autoantibodies 
play a role in the EAE animal model.
Multiple sclerosis (MS) is a chronic inflammatory disease of the brain and spinal cord that results in demyelina-
tion, neurodegeneration and axonal loss1. To date, no cure for MS has been identified, and although treatment for 
relapse-remitting MS focuses on reducing disease activity and progression, no treatment for the progressive types 
of MS has been identified2,3. One of the first-line therapies for MS is interferon-β (IFN-β), which functions by 
redirecting immunological responses from pro-inflammatory to anti-inflammatory T cell responses4. However, 
immunomodulatory treatments do not show long-term effects and have no effect on patients entering the pro-
gressive phase of MS2,4,5. B cells are another potential target for treating MS, and several types of anti-CD20 treat-
ments have shown efficacy in clinical trials6. Ocrelizumab is a new recombinant humanized antibody that targets 
CD20 antigen expressed on B cells and has shown efficacy in phase 3 trials for treatment of both relapse-remitting 
MS and primary progressive MS7,8.
Multiple sclerosis as an autoimmune disease
The etiology of MS remains unknown; however, environmental triggers in genetically susceptible individuals have 
been proposed as a model1,9,10. T cells are thought to be activated in the periphery through various mechanisms, 
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such as molecular mimicry, by-stander activation and exposure to bacteria present in the colon, and then to 
traffic to the central nervous system with activated B cells and monocytes. For more than two decades, this 
hypothesis has been proposed as the framework for understanding and treating MS as an autoimmune disease9. 
However, studies indicate that the T cell biology in MS is complex and that several T cell types play a role in MS 
pathogenesis11–13.
In recent years, the involvement of B cells and autoantibodies in MS has been re-examined, and they are 
both thought to play a central role in MS pathogenesis due to a correlation between disease progression and 
synthesis of intrathecal antibodies known as oligoclonal bands9,14–17. Nevertheless, limited knowledge is avail-
able about the antibody-antigen response in the brain and its role in disease induction and progression14,18,19. 
However, recent studies found that treatment with ocrelizumab, which functions by depleting CD20-expressing 
B cells, had beneficial effects on primary progressive MS and thereby reinforced the contribution of B cells to MS 
pathogenesis8. Specific posttranslational modifications have been shown to result in the loss of tolerance to the 
modified proteins, thus initiating antibody recognition20,21. A candidate for initiation of such an autoimmune 
response is a posttranslational modification termed citrullination, which naturally occurs on a myelin protein 
known as myelin basic protein (MBP). Citrullination is highly immunogenic, and antibodies against citrulline 
proteins are already used as diagnostic biomarkers in rheumatoid arthritis20,21. However, treating relapses with 
immunomodulatory therapies does not stop progression towards neurodegeneration and axonal loss, and as this 
effect indicates that the causes of lesions and neurodegeneration involve other mechanisms, key questions remain 
unanswered. Mechanisms underlying disease progression are proposed to involve an interaction between oxida-
tive stress, mitochondrial dysfunction, energy deficit and ion channel dysfunction, which are also suggested to 
be involved in neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral 
sclerosis (ALS)22,23.
Multiple sclerosis as a consequence of metabolic dysfunction
The traditional view of MS as a chronic inflammatory autoimmune disease is controversial. Alternatively, MS 
has been proposed to be a consequence of lipid metabolism dysfunction as well as mitochondrial dysfunction24. 
Studies have supported this hypothesis, as they have shown impaired glucose metabolism in MS25,26. Reduced 
glucose metabolism indicates a shift in metabolism towards lipid metabolism, which is consistent with previous 
reports of decreased lipid levels in MS lesions27,28. In addition, research has shown that T cells exposed to stress 
also induce a switch from glucose to lipid metabolism as an energy source, which underpins the importance of 
lipid metabolism in immune cells29. Carnitine palmitoyl transferase 1a (CPT1a) is a key enzyme involved in lipid 
metabolism, as it catalyzes the conversion of acyl-CoA (which is mitochondrial membrane-impermeable) into 
acyl-carnitine (which is mitochondrial membrane-permeable)29 [Mørkholt et al., submitted for publication]. This 
indicates that CPT1a serves as a rate-limiting enzyme in beta-oxidation29,30. CPT1a expression was found to be 
upregulated in MS lesions of the spinal cord31. Additionally, mutations in CPT1a resulting in either 22% activity 
or a dysfunctional molecule were found in two human populations in Canada, namely, the Inuits and Hutterites, 
respectively32–36. The incidence of developing MS was found to be 1/50,000 for the Inuits and 1/1100 for the 
Hutterites, which is rather low compared to the incidence of 1/350 in the Canadian population37,38. These findings 
suggest a role of CPT1a mutations in protecting against the development of MS. Although the particular mecha-
nism involved in the role of CPT1 in MS is unknown, it can be hypothesized that decreased CPT1 activity plays 
a protective role against mitochondrial dysfunction, as CPT1 plays an essential role in energy production from 
lipids, which thereby results in diminished production of reactive oxygen species (ROS). Furthermore, ROS and 
reactive nitrogen species (NOS) are both thought to be mediators involved in demyelination and axonal injury in 
MS and experimental autoimmune encephalomyelitis (EAE)39,40.
Chemical blockage of CPT1 by etomoxir enables a shift in metabolism that favors glucose metabolism rather 
than lipid metabolism as an energy source41–44 [Mørkholt et al., submitted for publication]. This CPT1 antagonist 
inhibits formation of acyl-carnitine, which is necessary for the transport of acyl-CoA into the mitochondria41. 
CPT1 inhibition presents a new treatment strategy that aims at both metabolism and immune system rather than 
focusing solely on inflammation as a therapeutic target. Studies by Shriver et al. and Mørkholt et al. supported 
this new hypothesis by showing that etomoxir treatment resulted in decreased disease activity and inflammation 
and increased remyelination in an EAE mouse model characterized by the expression of hallmarks of MS such as 
demyelination and inflammation11,29 [Mørkholt et al., submitted for publication]. This suggests that etomoxir is 
a novel potential treatment for MS.
This study aimed to investigate the efficacy of etomoxir and IFN-β treatment on the autoantibody response 
in EAE-induced and healthy animals using Western blot analysis and to identify and examine the levels of 
autoantibody reactivity for autoantigens recognized by these autoantibodies by immunoprecipitation and mass 
spectrometry.
Results
Disease score in an experimental autoimmune encephalomyelitis model. The impacts of the two 
treatments (etomoxir and IFN-β) and two treatment time points (days 1 and 5) were compared with those of the 
placebo treatment and control groups (Fig. 1). There were statistically significant differences in the disease score 
between animals treated with etomoxir on day 1 and animals treated with IFN-β on days 1 and 5 and placebo 
(p < 0.05 and p < 0.001). Moreover, animals receiving etomoxir on day 5 exhibited a significantly lower disease 
score than animals treated with IFN-β on day 1 (p < 0.01).
Detection of autoantibodies against brain proteins. Western blot analysis was performed to inves-
tigate the immunoglobulin G (IgG) antibody response against brain self-antigens in EAE-induced rats receiving 
placebo, IFN-β on day 1 or 5, or etomoxir on day 1 or 5 (Fig. 2). Autoantibodies against brain antigens were 
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Figure 1. Mean clinical score for animals in the EAE model; control (C, n = 5), placebo (P, n = 10), IFN-β 
on day 1 (I1, n = 10), IFN-β on day 5 (I5, n = 10), etomoxir on day 1 (E1, n = 10) and etomoxir on day 5 
(E5, n = 10). All data are presented as the mean ± SEM. Results from unpaired t-tests showed a statistically 
significant difference in the disease scores between E1 and I1, I5, and placebo. Treatment on E5 resulted in a 
significantly lower disease score than that on I1. Number of asterisks indicates level of statistical significance 
(*p < 0.05 and ***p < 0.001).
Figure 2. Western blots showing expression of brain antigens recognized by serum-derived antibodies; control 
(C), placebo (P), IFN-β on day 1 (I1), IFN-β on day 5 (I5), etomoxir on day 1 (E1) and etomoxir on day 5 (E5). 
Protein marker positions are indicated to the left (kDa). MBP bands are marked with arrows. Serum samples are 
derived from the same experiment. Each blot represents a sample from the different treatment groups, and blots 
were cropped and processed in parallel (a). Indirect ELISA showing the concentration (µg/ml) of serum-derived 
autoantibodies towards MBP in the presented blots (b). Indirect ELISA showing the concentration (µg/ml) of 
serum-derived autoantibodies towards MBP (c) and albumin (d) in all the animals. Data are presented as the 
mean ± SEM.
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detected in all animals, and interestingly, EAE- induced rats treated with etomoxir on day 1 showed weaker anti-
gen binding than the other treatment groups. All six groups revealed expression of MBP (Fig. 2a). The autoanti-
body response to MBP was validated by ELISA (Fig. 2b and c).
Detection of autoantigens recognized by autoantibodies in the brain. To investigate detection of 
antibodies to brain proteins further, immunoprecipitation was performed, and precipitated proteins were iden-
tified and quantified using label-free mass spectrometry. A Venn diagram of the identified proteins showed a 
high similarity in the number of precipitated proteins between groups (Fig. 3). The highest number of detected 
proteins in a sample was 123; of these proteins, seven were directly related to IgG (these proteins were discarded 
because they could have originated from serum antibodies), and 116 were suggested as self-antigens, including 
MBP and myelin proteolipid protein (PLP).
Interestingly, certain antigens in the control, placebo and treatment groups were highly similar; the lowest 
similarity percentage was 55%. The differences in the relative abundance, which potentially represents the anti-
body response, between the treatment groups and the placebo and control groups were investigated.
There were several significant differences in the quantification of autoantibody reactivity for antigens between 
the treatment groups and the placebo and control groups (Fig. 4, Supplementary Figure S1).
Some of the significant differences between the placebo and treatment groups were found on both treatment 
days (Fig. 5). The levels of relative autoantibody reactivity’s for apolipoprotein E (ApoE), clusterin, plasma pro-
tease C1 inhibitor, and serum amyloid P component (SAP) were all found to be decreased in etomoxir-treated 
animals, whereas antibody reactivity for serum albumin was found to be increased. The same changes were found 
in the control group for plasma protease C1 inhibitor and serum albumin levels. In IFN-β-treated animals, the 
autoantibody reactivity for complement component C9 and gelsolin were decreased, whereas the relative autoan-
tibody reactivity for PLP was upregulated, and only antibody reactivity for complement component C9 was the 
same as that in control animals.
Discussion
The clinical efficacy of the CPT1 inhibitor etomoxir was compared to that of the current first-line treatment 
IFN-β in an EAE model of MS. Animals treated with etomoxir on day 1 had a statistically significantly lower 
disease score at day 11 than animals receiving placebo, IFN-β on day 1 and IFN-β on day 5. Moreover, the group 
treated with etomoxir on day 5 obtained a significantly lower disease score than the IFN-β on day 1 treatment 
group. These lower disease scores obtained after etomoxir treatment indicate that blocking beta- oxidation in the 
mitochondria is a target for treating EAE and potentially MS. This result is consistent with the finding of Shriver 
and colleagues, who showed a beneficial effect of etomoxir treatment in an EAE model29. Furthermore, Bakshi 
et al. found that anti-lipid IgG antibodies were associated with the worsening of brain MRI measurements in 
MS patients45. Gonzalo et al. found significantly increased amounts of autoantibodies to lipoxidized proteins, 
indicating that lipid peroxidation is a pathogenic pathway in MS46. Regarding IFN-β-treated groups, Shirani et 
al. found that IFN-β treatment did not slow the progression of disability in MS patients, which is consistent with 
the findings of the present study5.
Western blot analysis showed weaker antibody signals following treatment with etomoxir on day 1 compared 
to the other treatments. This result could indicate a lower abundance of antibodies in the serum, which could be 
an effect of etomoxir treatment. As the blotting was directed against IgG antibodies, it is important to consider 
that the half-life of these antibodies is four to eight days in mice and could thus be similar in rats47. However, it is 
unlikely that such a decrease in antibody concentration would be substantial enough to have an obvious effect in 
late-treated animals. The high similarity between these potential autoantigens indicated that autoantibodies were 
present even in healthy animals, raising the question of why the autoimmune response was not active in control 
animals. This result could be due to low concentrations of antibodies, low affinity towards the antigen or an intact 
blood-brain barrier (BBB).
In the current study, the placebo group had significantly higher serum concentrations of antibodies against 
positive acute phase reactants (α1-acid glycoprotein, complement component C9, haptoglobin, ceruloplasmin, 
and plasma protease C1 inhibitor) and significantly lower serum concentrations of antibodies against negative 
acute phase reactants (transthyretin and α1-inhibitor-3) than the control group. These findings are consistent 
with the literature48–54. Furthermore, complement component C9 has been found to be directly correlated with 
Figure 3. Venn diagram of the immunoprecipitated proteins identified using mass spectrometry. Number of 
co-identified proteins corresponding to number of autoantibodies and percentages of similarity are shown in 
the treatment groups; control (C), placebo (P), IFN-β on day 1 (I1), IFN-β on day 5 (I5), etomoxir on day 1 (E1) 
and etomoxir on day 5 (E5).
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demyelination of the spinal cord55. A previous study showed elevated levels of hemopexin during the progression 
of disease in the EAE model, which is consistent with our findings56. In this study, EAE was induced by MBP 
suspended in complete Freund’s adjuvant; therefore, an antibody response to MBP was expected and was used as 
a positive control in this model57,58. The autoantibody response to MBP was validated by ELISA. The intensities 
of serum antibodies in the placebo group were consistent with the fact that the placebo group obtained a high 
Figure 4. Significant differences in the relative quantification between the treatment groups and the placebo (P) 
and control (C) groups. Treatments: E1 = etomoxir on day 1; E5 = etomoxir on day 5; I1 = IFN-β on day 1; 
I5 = IFN-β on day 5. SD under 2.0 on log2 scale.  significantly increased or  significantly decreased by at least 
a factor of 2. Number of asterisks indicates level of statistical significance (*p < 0.05 and **p < 0.01). More 
information can be found in Supplementary Figure S1.
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disease score, which implies that high levels of positive acute phase reactants and antigens and low levels of neg-
ative acute phase reactants are associated with EAE and possibly MS.
Furthermore, the two etomoxir-treated groups had significantly lower serum concentrations of antibodies 
against ApoE, clusterin, SAP, and plasma protease C1 inhibitor and a significantly higher serum concentration 
of anti-albumin antibody than the placebo group. Studies have shown an association between ApoE and MS59,60. 
Figure 5. Intensity of immunoprecipitated protein for all groups; apolipoprotein E (a), serum amyloid P 
component (b), clusterin (c), serum albumin (d), complement component C9 (e), gelsolin (f) and myelin 
proteolipid protein (g); control (C, n = 5), placebo (P, n = 10), IFN-β on day 1 (I1, n = 10), IFN-β on day 
5 (I5, n = 10), etomoxir on day 1 (E1, n = 10) and etomoxir on day 5 (E5, n = 10). All data are presented 
as the mean ± SEM. Results from the unpaired t-tests showed statistically significant differences in the 
immunoprecipitated protein intensities between P and E1 and E5 (a–d) and between P and I1 and I5 (e–g). 
Number of asterisks indicates level of statistical significance (*p < 0.05, **p < 0.01 and ***p < 0.001).
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Of note, Zhao et al. examined the effect of ApoE mimetic peptides in a mouse model of diffuse brain injury 
and found that ApoE mimetic peptides improved memory function and protected against neuronal apoptosis 
by inhibiting the ERK1/2 pathway and Bax expression. Moreover, malondialdehyde content was significantly 
decreased, and superoxide dismutase content was significantly increased61. Pang et al. showed that treatment 
with ApoE mimetic peptides in an experimental model of subarachnoid hemorrhage resulted in reduced deg-
radation of the BBB, which further resulted in less severe brain edema and neuron apoptosis, increased cere-
bral glucose uptake, and improved neurological functions. Moreover, the peptides inhibited cyclophilin, nuclear 
factor-kappaB, interleukin-6, tumor necrosis factor-α, and interleukin-1 and thus inflammation and BBB dis-
ruption62. This finding could indicate that the significant reduction in serum autoantibodies reactivity for ApoE 
resulted in decreased inactivation of ApoE and thereby a lower degree of inflammation, apoptosis and breakdown 
of the BBB, and this effect could explain the significantly lower disease score in etomoxir-treated animals than in 
placebo-treated animals. Furthermore, based on observations by Pang and colleagues, blocking lipid metabolism 
by etomoxir could also have an effect on the level of ApoE and result in normalization of glucose metabolism in 
the brain. Clusterin has been found to be upregulated in acute and chronic plaques in MS52. A previous study 
indicated that clusterin could be a marker of neurodegeneration in AD and PD and that its expression is increased 
during progression of AD63. Moreover, clusterin and complement factors leak into the brain during BBB break-
down64. These findings raise the question of whether the significant reduction in the relative autoantibody reac-
tivity for clusterin in etomoxir-treated animals could be the result of reduced degradation of the BBB. Moreover, 
clusterin facilitates the removal of apoptotic cells and thus diminishes autoimmune responses following cell 
death65. The lower levels of serum anti-clusterin antibodies and the lesser degree of disease in etomoxir-treated 
animals at day 1 and day 5 could indicate that clusterin facilitates the clearance of apoptotic cells. Ji et al. found 
that SAP might have a protective role in the development of EAE66. In support of their findings, Grant and col-
leagues found that treatment with amyloid β−40 or amyloid β-42 peptides reduced motor paralysis and brain 
inflammation in four different EAE models67. Furthermore, Kurnellas et al. showed that amyloidogenic peptides 
such as tau, amyloid-β A4 and SAP had anti-inflammatory properties, reduced serum levels of interleukin-6 
and reduced paralysis in EAE68,69. This finding could indicate that the significant decrease in serum anti-SAP 
antibodies resulted in decreased inactivation of SAP and thereby a lesser degree of inflammation. A review by 
Levine indicated that serum albumin has two side effects in the brain70: anti-pathogenic properties because it is a 
target for ROS and pro-pathogenic properties because it is pro-inflammatory, and high levels of serum albumin 
can lead to seizure. Furthermore, serum albumin leaks into the brain during BBB breakdown and is taken up by 
macrophages and cleaved during the acute phase of MS. In most healthy individuals anti-albumin antibodies 
have been found71, and it was therefore expected to detect these antibodies in control animals. Interestingly, in the 
EAE-diseased animals anti-albumin antibodies were decreased. These results were validated by ELISA.
IFN-β-treated animals at days 1 and 5 had significantly lower serum concentrations of antibodies against com-
plement component C9 and gelsolin than the placebo group. An earlier study found a direct correlation between 
the level of complement component C9 and demyelination of the spinal cord in an EAE model55. The lower serum 
antibody reactivity for complement component C9 could indicate that it is more active, which would result in 
demyelination and thereby a high disease score in IFN-β-treated animals72. Gelsolin is involved in myelin wrap-
ping and is decreased in cerebrospinal fluid and serum in MS but elevated in brain tissue73,74. The low serum con-
centration of anti-gelsolin antibody could indicate that myelin wrapping in IFN-β-treated animals was affected. 
Furthermore, IFN-β-treated animals at days 1 and 5 had significantly higher serum concentrations of antibodies 
against PLP than placebo-treated animals, which is consistent with the higher disease score in IFN-β-treated ani-
mals. However, etomoxir-treated animals at day 5 also showed higher serum levels of antibodies against PLP than 
placebo-treated animals, highlighting a potential topic of interest for further investigation.
In conclusion, this study indicated that etomoxir is a more effective treatment for MBP-induced EAE than 
IFN-β and placebo, as it resulted in a significantly lower disease scores. Additionally, the results indicate that 
etomoxir-dependent inhibition of mitochondrial beta-oxidation in the EAE rat model is effective because of the 
regulation of serum autoantibodies against proteins such as ApoE, clusterin, SAP, and serum albumin, suggesting 
a role of these antigens in the progression of EAE and their potential use as diagnostic biomarkers for MS.
Materials and Methods
Experimental autoimmune encephalomyelitis rat model. Animal experiments were conducted 
according to NIH guidelines and were approved by the Danish National Committee for Ethics in Animal 
Experimentation (2015-15-0201-00647). Two-month-old female Lewis rats were obtained from Charles River 
Laboratories, Inc., Germany. The rats were housed under standardized conditions with 12 h light/dark cycles and 
free access to food and water. The rats were anesthetized with isoflurane (Baxter Laboratories) and then intrader-
mally injected in the base of the tail with an emulsion consisting of 100 µg of MBP (Sigma-Aldrich) suspended 
in saline and complete Freund’s adjuvant (Becton Dickinson) and supplemented with 0.2 µg of Mycobacterium 
tuberculosis (Becton Dickinson). EAE was induced in 45 rats, and five rats were used as controls and thus were not 
EAE-induced. Rats were treated daily with either etomoxir (Meta-IQ ApS, Denmark) or IFN-β (Extavia, Aalborg 
University Hospital, Denmark) on the first or fifth day of induction. Etomoxir was heated to 37 °C and dissolved 
in olive oil. Etomoxir was subcutaneously administered every day at a dosage of 1 mg/kg. Interferon-β was subcu-
taneously administered every other day at a dosage of 200,000 IU. The placebo group received daily injections of 
olive oil. All rats were weighed and clinically scored on a daily basis according to a scale from zero to five75: zero, no 
clinical signs of EAE; one, limp tail; two, paresis of one or two hind limbs; three, unilateral hind leg paralysis; four, 
bilateral hind leg paralysis; and five, bilateral hind leg paralysis and incontinence or moribund. Moreover, animals 
were not permitted to lose more than 20% body weight compared to their weight at the time of EAE induction. 
Rats were euthanized. Then, blood samples were obtained by cardiac puncture, and collected blood samples were 
labeled according to the groups. Blood samples were used for Western blot, ELISA and immunoprecipitation.
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Western blot. Preparation of rat brain sample. Cerebellum from three-week-old Sprague-Dawley rats was 
isolated, and protein homogenates were prepared by transferring the cerebellum to a dissection buffer containing 
10% sucrose (VWR), imidazole (Merck Millipore), EDTA (Sigma-Aldrich), Pefabloc (Sigma-Aldrich) and leu-
peptin (VWR). The mixture was homogenized (T10 basic ULTRA-TURAX homogenizer IKA®) for 20 sec; then, 
samples were centrifuged at 1000 g for 15 min. Supernatants were stored at −20 °C.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Brain homogenate samples were diluted in dissection 
buffer. Then, sample buffer (Bio-Rad) and 5% beta- mercaptoethanol (Sigma-Aldrich) were added to the brain 
homogenate solution at a 1:1 ratio. Samples were incubated for 15 min at 65 °C. Precision Plus Protein Standard 
Ladder (Bio-Rad) was used as a reference. Western blots of total rat brain tissue were separated on 4–15% 
Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) using a Mini-PROTEAN Tetra Cell system (Bio-Rad).
Blotting. Proteins were transferred to polyvinylidene fluoride membranes (Bio-Rad) by using a Trans-Blot 
Turbo Transfer System (Bio-Rad). Membranes were stained with 0.1% Ponceau S (MP Biomedicals; diluted in 
1% acetic acid (VWR) and Milli-Q water) for 10 min, and gels were stained with Coomassie (Sigma-Aldrich) for 
15 min. After washing three times in Milli-Q water, membranes and gels were respectively destained in 1% acetic 
acid in Milli-Q water for one hour and 10% ethanol, 7.5% acetic acid in Milli-Q water overnight, respectively. 
Membranes were cut vertically into lanes and blocked in 5% skimmed milk (VWR) diluted in 0.1% Tween- 20 
(Sigma-Aldrich) in PBS (PBS-T) for one hour on a table shaker at room temperature. Then, membranes were 
washed three times in PBS-T and incubated overnight on a table shaker at 4 °C with sera (1:100; diluted in 1% 
BSA, 0.1% NaN3 in PBS-T) from healthy rats or EAE-induced rats that received placebo, etomoxir or IFN-β. After 
washing three times in PBS-T, membranes were incubated with rabbit anti-rat secondary antibody conjugated 
with HRP (cat#61-9520, Thermo Scientific) diluted in 5% skimmed milk in PBS-T (1:1000) for one hour on a 
table shaker at room temperature. Membranes were washed three times in PBS-T and subsequently incubated in 
Amersham ECL Prime Western blot Detection Reagent (GE Healthcare) for 1 min. Membranes were then visual-
ized using an Odyssey Fc Imaging System (Li-Cor Biosciences) with LI-COR Image Studio™ software.
Indirect Enzyme-Linked ImmunoSorbent Assay. Wells were coated with a protein concentration of 
10 µg/ml of rat MBP (cat#2295, Sigma-Aldrich) or rat albumin (cat#A6414, Sigma-Aldrich) overnight at 4 °C. 
The coated wells were blocked by adding blocking buffer containing 0.1% Tween-20 (Sigma-Aldrich) and 5% 
skimmed milk (VWR) in PBS, and incubated for one hour at room temperature. The wells were washed three 
times in PBS. Afterwards, serum samples diluted in blocking buffer (1:100) were added and incubated for one 
hour at room temperature. At the same time, standards were prepared in a range of 1:10 to 1:100000 using rat 
anti-MBP (cat#ab7349, Abcam) and rabbit anti-albumin (cat#ab207327, Abcam) antibodies diluted in blocking 
buffer and incubated for one hour at room temperature. All samples and standards for MBP were run in triplicates 
and in duplicates for albumin. After incubation, all wells were washed three times in PBS. Secondary antibodies, 
rabbit anti-rat conjugated with HRP (cat#61-9520, Thermo Scientific) and goat anti-rabbit conjugated with HRP 
(cat#P0448, Dako) diluted in blocking buffer (1:2000), were added and incubated for one hour at room tempera-
ture. All wells were washed four times in PBS and then 3,3′5,5′-tetramethylbenzidine (Sigma-Aldrich) were added 
and incubated for 15 min at room temperature. Following incubation, stop solution containing MilliQ-water and 
2 M H2SO4 (1:1) were added. Subsequently, the optical density was read at 450 nm using EnSpire Multimode Plate 
Reader. The concentration of autoantibodies was calculated using the standard curves in GraphPad Prism 7.
Immunoprecipitation. Preclearing. A mixture of antibody buffer containing 1% BSA, 0.1% 2 M NaN3 in 
PBS-T and A/G magnetic beads (Pierce Protein Biology, Thermo Scientific) was prepared and transferred to a 
tube in a magnetic stand. Then, the supernatant was discarded, and the magnetic beads were collected. Antibody 
buffer was added to the magnetic beads mixture and vortexed. The mixture was then added to brain homogen-
ate obtained from cerebellum of a three-week-old Sprague-Dawley rat and incubated on ice for one hour. Next, 
this solution was transferred to the magnetic stand, and the beads were collected, washed three times in anti-
body buffer and subsequently stored at 4 °C. The supernatant was collected, and additional magnetic beads were 
added and incubated on ice for 30 min. This step was repeated three times, and antibody buffer was added to the 
supernatant.
Immunoprecipitation. A total of 1 µl of serum from healthy rats and EAE-induced rats receiving placebo, etomoxir 
or IFN-β, was used for immunoprecipitation experiments. Precleared brain homogenate, which was the same for all 
groups, was mixed with serum from EAE animals and incubated on ice for one hour. Magnetic beads were added to 
each sample and incubated on ice for one hour. After incubation, samples were placed in a magnet stand to isolate 
the beads, which were washed three times in antibody buffer and then eluted by incubating in 120 mM sodium 
deoxycholate (SDC) in 50 mM triethylammonium bicarbonate (TEAB) (pH 8.5) for 10 min at 95 °C.
Proteomics sample preparation. Proteomic sample preparation was performed according to a FASP 
digestion protocol by Bennike et al., in which samples are prepared with ethyl acetate phase inversion to facilitate 
surfactant removal76. The eluate was transferred to individual YM-10 kDa spin filters for digestion (Millipore, 
Billerica, MA, USA) and centrifuged at 14,000 g for 15 min at room temperature, which were the settings for all 
future performed centrifugation steps. Protein disulfide bonds were reduced with 12 mM tris(2-carboxyethyl)
phosphine (Thermo Scientific) and alkylated with 50 mM chloroacetamide (Sigma-Aldrich) for 30 min at 37 °C, 
followed by centrifugation. Reducing and alkylating agents were dissolved in 120 mM SDC/50 mM TEAB 
(pH 8.5). In preparation for digestion, 10 mM CaCl and 50 mM TEAB buffer was added to the spin filter and 
www.nature.com/scientificreports/
9SCieNTifiC RepoRts |  (2018) 8:7092  | DOI:10.1038/s41598-018-25391-y
centrifuged. A 1:25 (w/w) chymotrypsin:protein ratio dissolved in digestion buffer was added to the spin filter, 
and the samples were digested overnight at 37 °C. Flow-through, containing the peptides, was retrieved by addi-
tion of 50 mM TEAB buffer and centrifugation. To facilitate SDC removal, a phase separation was performed 
with 3:1 (v/v) ethyl acetate:sample and acidified by addition of trifluoroacetic acid (TFA) to a final concentration 
of 0.5%. Total phase separation was achieved by 2 min agitation followed by centrifugation. The aqueous phase 
was collected and vacuum centrifuged overnight, and the dry peptide product was stored at −80 °C until analysis.
Mass spectrometry analysis. Peptides were resuspended in a solution containing 2% acetonitrile (ACN), 
0.1% formic acid (FA) and 0.1% TFA, and then, peptides were briefly sonicated. Five micrograms of total peptide 
material were analyzed per liquid chromatography–mass spectrometry analysis. Samples were analyzed using a 
UPLC-nanoESI MS/MS setup with a NanoRSLC system (Dionex). The system was coupled online with an emitter 
for nanospray ionization (New Objective PicoTip 360-20-10) to a Q Exactive HF mass spectrometer (Thermo 
Scientific). The peptide material was loaded onto a 2-cm trapping reversed-phase Acclaim PepMap RSLC C18 
column (Dionex) and separated using an analytical 75-cm reversed-phase Acclaim PepMap RSLC C18 column 
(Dionex). Both columns were kept at 60 °C. The sample was eluted with a gradient of 90% solvent A (0.1% FA, 
0.1% TFA) and 10% solvent B (0.1% FA, 0.1% TFA in ACN), which was increased to 7% solvent B on a 1-min 
ramp gradient at a constant flow rate of 300 nL/min. Subsequently, the gradient was raised to 30% solvent B on a 
45-min ramp gradient. The mass spectrometer was operated in positive mode, selecting up to 20 precursor ions 
with a mass window of m/z 1.6 based on highest intensity for higher-energy collisional dissociation (HCD) frag-
menting at a normalized collision energy of 27. Selected precursors were dynamically excluded for fragmentation 
for 30 sec.
Protein identification and quantitation analysis. A label-free relative quantitation analysis was per-
formed using MaxQuant 1.5.7.4 software. Raw files were searched against the Rattus norvegicus UniProt data-
base (proteome ID UP000002494)77,78. All standard settings were employed with carbamidomethylation (C) as a 
static peptide modification and deamidation (NQ), oxidation (M), formylation (N-terminal and K), and protein 
acetylation (N-terminal) as variable modifications. The output contained a list of proteins identified below 1% 
false discovery rate, and their abundances were further filtered and processed using Perseus v1.5.6.0 platform. All 
reverse hits that identified proteins were removed from further analysis, and the data were log2-transformed in 
order to approximate normal distribution. Two or more unique peptides were required for protein quantitation. 
Additionally, a non-zero quantitation value in at least 70% of the samples in one of the groups was required for 
the quantifiable proteins. A Venn diagram was generated using FunRich software to compare the number of 
proteins that were present in 70% of the samples in each group79. The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier 
PXD00883580,81.
Applied statistics. Disease score data were analyzed by unpaired t-tests. ELISA data were quantified by 
interpolating samples according to a standard curve and groups were analyzed by one-way ANOVA. Quantifiable 
proteins identified in the different groups were compared in a Venn diagram, and to investigate differences in the 
expression of proteins between the groups, unpaired two-tailed t-tests were performed. All data are presented as 
the mean ± SEM. P values of 0.05 were used as a cut-off.
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Blocking of carnitine palmitoyl 
transferase 1 potently reduces 
stress-induced depression in rat 
highlighting a pivotal role of lipid 
metabolism
Anne Skøttrup Mørkholt1, Ove Wiborg2, Jette G. K. Nieland3, Søren Nielsen1 & John Dirk 
Nieland1
Major depressive disorder is a complex and common mental disease, for which the pathology has 
not been elucidated. The purpose of this study is to provide knowledge about the importance of 
mitochondrial dysfunction, dysregulated lipid metabolism and inflammation. Mitochondrial carnitine 
palmitoyl transferase 1a (CPT1a) is a key molecule involved in lipid metabolism and mutations in CPT1a 
causing reduced function is hypothesized to have a protective role in the development of depression. 
Moreover, CPT1a is found to be upregulated in suicide patients with history of depression. Therefore, 
we hypothesized that inhibition of CPT1a activity can be developed as an innovative treatment 
strategy for depression. Stress exposure combined with different pharmacological treatment regimens; 
Etomoxir, CPT1 blocker, and Escitalopram, a favoured antidepressant drug, was applied in state-of-the-
art chronic mild stress model. Etomoxir treatment induced statistical significant reduction of anhedonic 
behavior compared to vehicle treatment (p < 0.0001) and reversed depression-like phenotype in 90% 
of the rats (p = 0.0007), whereas Escitalopram only proved 57% efficacy. Moreover, Etomoxir revealed 
downregulation of interferon-γ, interleukin-17α and tumor necrosis factor-α. This indicate that 
alteration in metabolism is pivotal in the pathogenesis of depression, since CPT1 blockage is highly 
efficient in treating anhedonia and inflammation, thereby opening up for a novel class of antidepressant 
medication.
Major depressive disorder is a common and complex disease characterized by prolonged periods of suppressed 
mood and anhedonia, which is defined as loss of interest or pleasure in all or almost all activities1–3. Depression 
affects 350 million people worldwide and in 2030 predictions from WHO indicate that depression will be one of 
the largest causes of the disease burden globally4. The most commonly prescribed antidepressant treatment is 
selective serotonin reuptake inhibitors (SSRIs)5, 6. The antidepressant treatment used today has only shown mod-
erate response rates of up to 50–60%5. This indicates that there is a large number of patients that respond inade-
quately to treatment, thereby underscoring the need for more effective treatment of depression. The pathology of 
depression has not been elucidated yet, but different theories have been proposed. This study focuses on a novel 
concept concerning upregulated lipid metabolism, based on several studies have shown an association between 
serum lipid concentrations and depression in patients7–9. A study by Chen et al. showed a significant reduction in 
serum triglycerides and high-density lipoprotein cholesterol in depressed patients7. This indicates that alteration 
in lipid metabolism is involved in the pathology of depression7, 8, 10.
Glucose and fatty acids are both used for cellular energy production during glycolysis and beta oxidation, 
respectively11. In beta oxidation, fatty acyl groups are transported from the cytosol and through the outer and 
inner mitochondrial membrane12. However, the impermeability of the mitochondrial membrane to acyl-CoA 
molecules necessitates the shuttling of acyl-CoA through the outer mitochondrial membrane by carnitine, 
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which is catalyzed by carnitine palmitoyl transferase 1 (CPT1)13. CPT1 facilitates transfer of the acyl group from 
CoA to carnitine, thereby enabling transport of the acyl-carnitine through the outer mitochondrial membrane 
towards the mitochondrial matrix. Via the translocase the acyl-carnitine is transported to the matrix and there 
converted back to acyl-CoA catalyzed by carnitine palmitoyl transferase 2 (CPT2)13. Conversion of acyl-CoA to 
acyl-carnitine by CPT1 is the rate limiting step and CPT1 thus becomes a key regulator of the metabolism of the 
cell12. In diseases like cardiomyopathy, and psoriasis it has been shown that increased CPT1 expression is directly 
correlated with disease state14, 15. Although the exact role of CPT1 in depression is not known it is tempting to 
hypothesize that there is a link between CPT1 mediated lipid transport and depression due to its central role in 
cellular energy production from lipids and the fact that there is reduced lipid levels in depressed patients.
A potent blocker of CPT1, rate limiting for fatty acid metabolism and hence lipid metabolism, called Etomoxir 
is able to reverse the shift in metabolism, thereby favouring glucose metabolism as an energy source rather 
than lipids16–18. Etomoxir, a CPT1 antagonist, binds specifically to CPT1 and thus prevents the formation of 
acyl-carnitine, which is a necessary step for the transport of fatty acyl-CoA into the mitochondria16. This treat-
ment regimen focusing on the metabolism is fundamentally very different from the most common treatment 
rationales of depression, which are generally based on the use of antidepressants stimulating monoaminergic 
transmission5. Under conditions with stress exposure metabolism shifts from using glucose, the primary energy 
source of the central nervous system, to fatty acids as energy source12, 19–21. Stress can be caused by internal or 
external events. Internal events include traumatic head injury and hormonal challenges, whereas external stress-
ors encompass major adverse life events like bereavement or accumulation of minor stressors for example pov-
erty, unemployment and family disharmony6. These different types of stressors formed the basis of establishing 
the chronic mild stress (CMS) model in rodents22. The CMS model is a state-of-art validated model mimicking 
depression by relying on the application of realistic stressors and thus incorporating the cardinal symptom, anhe-
donia, and thereby inducing a decrease in responsiveness to reward1, 22. The CMS protocol consists of exposure 
to a variety of stressors, e.g. food or water deprivation, tilting of cages, isolation or crowded housing, changing 
dark-light cycle etc., which results in behavioural deficits and decreased reward sensitivity1. Consequently, this 
leads to suppressed preference or consumption of a palatable sucrose solution, which therefore becomes a repet-
itive readout on the hedonic status of the rats and thereby becomes a rating measurement on the severity of the 
depression-like state23.
The purpose of the present study is to clarify the role of lipid metabolism on the development of depression 
by examining the effect of a blocker of lipid metabolism, Etomoxir, in the CMS model and compare it to a current 
standard treatment of depression, Escitalopram. Moreover, we want to examine the effect of Etomoxir on inflam-
mation induced by a bacterial agent in human peripheral blood lymphocytes.
Results
Expression of carnitine palmitoyl transferase 1a mRNA in depressed patients. The expression of 
CPT1a mRNA in pathological brain samples of patients that committed suicide with a history of depression and 
compared non-depressed controls that committed suicide was analyzed by affymetrix analysis (Table 1). Results 
from this analysis showed a significant upregulation of CPT1a expression in cerebellum (p = 0.0021). There was 
no significant upregulation of CPT1a mRNA in the inferior temporal gyrus, nucleus accumbens and hippocam-
pus (p = 0.0614, p = 0.0682 and p = 0.4831), although there was tendency of upregulation in these brain regions.
Treatment of stress-induced depression by blocking carnitine palmitoyl transferase 1. Rats 
were initially exposed to four weeks of CMS and subsequently exposed to stressors for another five weeks com-
bined with drug or vehicle treatment (Fig. 1). The intake of sucrose solution was measured in order to determine 
the anhedonic status among rats. There was no significant difference between rats receiving vehicle treatment 
compared to groups receiving Escitalopram. In a separate group rats were treated with Etomoxir while exposed 
to stress for five weeks and compared to a vehicle group exposed to stress and an unchallenged control group. 
The intake of sucrose solution was significantly higher in rats treated with Etomoxir compared to the vehicle 
group in all five weeks (p = 0.0013, p = 0.0001, p = 0.0157, p < 0.0001 and p < 0.0001). Moreover, statistical signif-
icant difference was found between Escitalopram and Etomoxir treatment in week two, four and five (p = 0.0175, 
p = 0.0455 and p = 0.0004) revealing a significantly higher efficacy of Etomoxir compared to Escitalopram treat-
ment. Treatment with Etomoxir during CMS exposure increased the level of sucrose intake to the same level as 
for unchallenged rats after five weeks of treatment. The total intake of sucrose was compared in all five groups 
after five weeks of treatment (Fig. 2). Statistically significant difference was found between rats exposed to stress 
treated with Etomoxir and CMS rats receiving vehicle (p = 0.0441). No significant differences were observed 
between unchallenged controls receiving vehicle or Etomoxir and stress exposed rats receiving Etomoxir. The 
percentage of animals responding over time receiving Etomoxir, Escitalopram or vehicle was compared (Fig. 3). 
The criterion for responders was set at an operational cut-off of 20% increase in intake of sucrose at the respective 
Tissue CPT1a expression (Control) n CPT1a expression (Depression) n Fold change P-value
Cerebellum 5.96 10 16.55 10 2.78 0.0021
Inferior temporal gyrus 8.60 8 15.01 14 1.75 0.0614
Nucleus accumbens 6.12 7 10.93 13 1.78 0.0682
Hippocampus 10.25 9 11.91 13 1.16 0.4831
Table 1. mRNA expression of CPT1a.
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weeks compared to baseline prior to onset of treatment. The effect of treatment with Etomoxir and Escitalopram 
was almost the same in week one and three, whereas the percentage of responding rats to Etomoxir treatment 
was higher than Escitalopram treatment in week two, four and five. Treatment with Escitalopram showed 57% 
Figure 1. Comparison over time of the efficacy of Etomoxir and Escitalopram in chronic mild stress-induced 
depression. Baseline values indicate sucrose intake after four weeks of stress exposure. Sucrose intake in 
gram during five weeks of treatment with Escitalopram (n = 14, downwards triangle), Etomoxir (n = 20, 
square) or vehicle (n = 9, circle) with continuous chronic mild stress exposure. Unchallenged control group 
was not exposed to the stress protocol but received vehicle treatment (n = 9, triangle). All data are presented 
as mean ± SEM. The results from the repeated measures two-way ANOVA (interaction F = 2.31, DF = 15, 
p = 0.0043; time F = 2.21, DF = 5, p = 0.0535; treatment F = 13.63, DF = 3, p < 0.0001) with Tukey multiple 
comparisons post hoc test showed statistical significance between vehicle and Etomoxir (*), and Escitalopram 
and Etomoxir (§). Number of asterisks/paragraphs indicates level of statistical significance (*p = 0.01–0.05, 
**p = 0.001–0.01, ***p = 0.0001–0.001, ****p < 0.0001).
Figure 2. Treatment efficacy in the different groups after five weeks of drug treatment. All data are presented 
as mean ± SEM. The results from the one-way ANOVA (F = 4.178, DF = 4, p = 0.0052) with a Tukey multiple 
comparisons post hoc test showed statistical significance between CMS exposed animals receiving vehicle and 
Etomoxir. Number of asterisks indicates level of statistical significance (*p = 0.01–0.05).
Figure 3. Percentage of responding animals in all five weeks of treatment. Etomoxir or Escitalopram 
administration reveal similar percentage of responding animals in week one and three, however treatment with 
Etomoxir shows higher percentage of responders in week two, four and five compared to Escitalopram.
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hedonic rats after five weeks of treatment with concomitant exposure to stress (Fig. 4). No significant difference 
was found in treatment efficacy of Escitalopram when comparing to vehicle. Etomoxir reversed the CMS sucrose 
drinking behaviour in 90% of the rats compared to baseline. In vehicle treated CMS exposed rats 22% recovered 
partly which was likely due to habituation to stressors. The difference in treatment efficacy between Etomoxir and 
vehicle treatment was statistically highly significant (p = 0.0007).
The effect of carnitine palmitoyl transferase 1 downregulates blockage on the immune sys-
tem. Human peripheral blood lymphocytes were stimulated with the T cell activating agent, staphylococcal 
enterotoxin b (SEB), for 48 hours in order to activate the immune system (Fig. 5). An unstimulated group and 
a SEB stimulated group were treated with Etomoxir. The human peripheral blood lymphocytes were gated for 
CD3+ cells. Unstimulated lymphocytes receiving Etomoxir and no SEB treatment showed low production of all 
cytokines measured. SEB stimulated lymphocytes receiving Etomoxir treatment revealed 49%, 64% (p = 0.0037) 
and 44% downregulation of interferon-γ (IFN-γ), interleukin-17α (IL-17α) and tumor necrosis factor-α 
(TNF-α).
Discussion
The traditional way of thinking depression such as impairment in a single brain substructure or a single neuro-
transmitter system is no longer approved. Rather it has become evident that much more complex systems are 
underlying the depression pathology24. Imbalance in monoaminergic neurotransmission, impaired neurogenesis 
in hippocampus, high levels of glucocorticoids and inflammation in CNS are all well-founded theories describing 
the pathogenesis of depression25, 26. Established hypotheses may still be partly operative although they are incom-
plete in explaining the entire etiopathogenesis of depressive disorder and do not account for the inadequacy in 
conventional antidepressant treatment regimens either. Novel hypotheses, appreciating the etiology of the dis-
ease, are on demand for the development of more effective and safe antidepressants. Therefore, a new hypothesis 
involving upregulated lipid metabolism, as a consequence of persistent stress exposure, is potentially a main 
Figure 4. Percentage of hedonic animals after treatment with Escitalopram and Etomoxir. The results from 
Fischers exact test showed significant difference between treatment with Etomoxir (n = 20) and vehicle (n = 9)
(***p = 0.0001–0.001). There was no statistical significance between Escitalopram (n = 14) and vehicle.
Figure 5. Human peripheral blood lymphocytes stimulated with staphylococcal enterotoxin B (SEB) for 48 h 
and gated for CD3+ cells. SEB stimulation activates the immune system. All data are presented as mean ± SEM. 
The results from the two-way ANOVA (interaction F = 3.576, DF = 6, p = 0.0287; cytokine F = 7.362, DF = 3, 
p = 0.0082; treatment F = 14,83, DF = 2, p = 0.0002) with a Tukey multiple comparisons post hoc test showed 
statistical significant difference in percentage of interleukin-17α positive cells between SEB stimulated cells and 
SEB stimulated cells receiving Etomoxir (**p = 0.001–0.01).
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underlying driver and comprises possibly a missing link in understanding the pathophysiology of depression. 
This kind of consideration is a novel way of thinking the pathogenesis.
Lipids play an important role in normal neuronal functioning of the brain, as they are involved in signaling 
processes of the cell27. Endocannabinoids, a class of lipid mediators, are found in several tissues and involved in 
processes as neuronal signaling, immune responses, cell survival and apoptosis28. These endocannabinoids are 
thought to provide neuroprotection via cannabinoid receptors. Lipids, as arachidonic acid and docosahexaenoic 
acid, constitute approximately 20% of lipids in the brain, and therefore essential for maintenance of a normal 
brain metabolism29, 30. Imbalance in the composition of these important lipids is associated with several brain dis-
eases29. Derivatives of arachidonic acid, e.g. N-arachidonoyl-dopamine, activates the cannabinoid type-1 receptor 
resulting in increased dopamine release28, 31. Both dopamine and cannabinoid neurotransmission is involved in 
emotional and motivational behavior28, 31–35. With an upregulated lipid metabolism follows a decreased level of 
serum lipids, which is a finding associated with depression7, 8. CPT1 is a key enzyme in lipid metabolism as it 
catalyzes the rate-limiting step in beta oxidation12, 36. We found a significant upregulation of CPT1a mRNA lev-
els in cerebellum of people with history of depression which committed suicide, compared to healthy controls. 
This suggests an association between CPT1a upregulation and depression, as a consequence of upregulated lipid 
metabolism. Liu et al. concluded that network alterations in cerebellum is associated with cognitive emotional 
impairments in depression37. We also found CPT1a mRNA upregulation in inferior temporal gyrus, nucleus 
accumbens and hippocampus, though these upregulations of CPT1a mRNA were not statistically significant 
different compared to controls. Additionally, two ethnic populations, called Hutterites and Inuits, both living 
in Canada have two different mutations in CPT1a, which either makes the protein dysfunctional (Hutterites) or 
decreases the activity to 22% (Inuits) (Table 2)38–42. In these populations the life time prevalence rates of depres-
sion is 0.35% and 3%, respectively, which is rather low compared to the rate in the gross Canadian population at 
16%43, 44. Whether these low rates of depression is caused by genetic or environmental alterations is unknown, 
however, the finding of CPT1a mutations in the Hutterite and Inuit population supports the novel theory in this 
study stating that a decreased activity of CPT1 increases resiliency for developing depression45.
Blocking the lipid metabolism by Etomoxir, a CPT1 antagonist, we therapeutically downregulate the activity 
of CPT1, and thereby also CPT1a. This highlights a new mechanism of action for novel antidepressant medica-
tion, which is examined in this study using the CMS model. Studies suggesting alterations in fatty acids and lipid 
metabolism demonstrated antidepressant effects of l-acetyl-carnitine treatment in mice46, 47. This treatment is 
comparable with blockage of CPT1a, since this also leads to increased acetyl-carnitine levels. However, Etomoxir 
treatment has in addition anti-inflammatory effects. This result underpins the theory and findings of this study 
regarding blockage of lipid metabolism as a potent antidepressant treatment strategy. Rats exposed to the CMS 
model, thus developing anhedonic behavior, received Etomoxir and showed significant increased intake of 
sucrose in all five weeks compared to the vehicle group. Moreover, the response rate of Etomoxir was higher than 
the response rate of Escitalopram, as 90% of the animals responded to Etomoxir treatment, while only 10% were 
classified as non-responders. Treatment with Etomoxir resulted in a statistically significant higher percentage of 
responding animals compared to vehicle treatment showing only 22% healthy rats after five weeks of treatment. 
All animals from each group were included, therefore there was no significant effect of Escitalopram. When ana-
lyzed at an individual basis 60% of the Escitalopram treated animals were classified as drug-responders, which is 
in the range that we have observed repeatedly in previous studies2. Comparison of sucrose intake after five weeks 
of treatment in all groups demonstrated that treatment with Etomoxir was significantly different from vehicle 
treatment. Moreover, the intake of sucrose after Etomoxir treatment was almost equal to the sucrose intake of 
unchallenged rats indicating that Etomoxir is able to reverse the anhedonic behaviour of rats exposed to stressors. 
The principle underlying Etomoxir treatment strategy is dramatically different from that of SSRIs, which increases 
the level of extrasynaptic serotonin. A disadvantage of conventional antidepressants is slow onset of antidepres-
sant action6. Thus it takes several weeks before SSRIs are therapeutically effective48. Etomoxir treatment showed 
major effects after week one with a response rate of approximately 70% and 90% after five weeks of treatment. 
Additionally, Etomoxir revealed a significant higher percentage of responding animals in all five weeks compared 
to Escitalopram and vehicle.
Studies have suggested a correlation between depression and immune dysregulation as increased levels of 
pro-inflammatory cytokines were found in depressed patients compared to healthy subjects25, 26, 49. It has been 
shown that increased activity of CPT1a results in increased inflammatory and memory T cell responses50. 
Therefore, inhibition of CPT1 by Etomoxir is predicted to decrease the inflammatory response. This was sup-
ported by data from this study, in which human peripheral blood lymphocytes were stimulated with SEB, a bac-
terial antigen, in the presence or absence of Etomoxir. Treatment with Etomoxir mediated downregulation of 
cytokines IFN-γ, IL-17α and TNF-α of 49%, 64% and 44%, respectively, which were upregulated by SEB stimu-
lation. These have, among others, been suggested to be involved in the pathogenesis of depression although the 
exact pathophysiological mechanism is still unknown51. Several studies have demonstrated inflammatory changes 
CPT1a mutation % CPT1a activity % people with mutation Depression rates
Canadian population Wild type 100%42 ~0%39 16%44
Hutterites 2129 G to A → AA710 Gly to Glu ~0%
38–40, 42 60%39 0.35%43
Inuits 1436 C to G → AA479 Pro to Leu 22%
41, 42 98%57 3%44
Table 2. Carnitine palmitoyl transferase 1a (CPT1a) mutations in humane populations.
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in the brain of depressed patients52–54. Moreover, a study regarding the experimental autoimmune encephalomy-
elitis model of multiple sclerosis found that treatment with Etomoxir revealed reduced demyelination of neurons 
and reduced infiltration of immune cells in the CNS thereby counteracting inflammatory responses12. All these 
findings indicate that Etomoxir has anti-inflammatory effects and lipid metabolism plays a role in supporting 
the inflammatory response within the CNS12. The data presented in this study has motivated us to propose a new 
hypothesis of depression suggesting that the pathophysiology of depression is a combination of both dysregulated 
lipid metabolism and dysregulated immune response.
We demonstrated that inhibition of CPT1 by systemic application of Etomoxir has beneficial effects in the 
treatment of depression in a highly validated CMS depression model. The model has unique predictive validity in 
antidepressant drug screening, essentially without any false positives. Moreover, treatment with Etomoxir showed 
significantly higher intake of sucrose compared to Escitalopram and vehicle, and also higher response rate of up 
to 90%. We also demonstrated an anti-inflammatory effect of Etomoxir as the levels of cytokines, IFN-γ, IL-17α 
and TNF-α, were downregulated compared to controls. Treatment with Etomoxir and thereby blocking the lipid 
metabolism paves the way for rethinking strategies in the development of novel treatment regimens of depression.
Methods
Affymetrix Analysis. Tissue was isolated from people that committed suicide. The CPT1a expression anal-
ysis was performed on tissue selected from either patients with history of depression or non-depressed controls. 
Tissue from patients or healthy donors has been isolated according to Gene Logic protocols. Ethical and medical 
approvals were obtained by Gene Logic, Inc. 708 Quince Orchard Rd. Gaithersburg, MD 20878. Afterwards the 
mRNA was purified and analyzed for expression of CPT1a in affymetrix analysis (Affymetrix ID 203634_s_at 
and 210688_s_at) Genbank ID: NM_001876, and expression was analyzed with GeneExpress® and e-NorthernTM 
proprietary informatics programs of Gene Logic.
Animals. The animal experiment was conducted according to NIH guidelines and was approved by the 
Danish National Committee for Ethics in Animal Experimentation (2008/561-477). Male Wistar rats purchased 
from Taconic, Denmark, were used for the CMS model. The weight of the rats was approximately 200 g when 
the experiment was initiated and approximately 350 g when stress exposure was initiated. The rats were housed 
singly with 12 h light/dark cycle and food and water was available ad libitum except when these parameters were 
applied as stress inducers. The following paragraphs concerning the CMS model was performed according to the 
protocol by Jayatissa et al.55.
Chronic Mild Stress protocol. The animals were divided into two groups; one group was exposed to stress 
and one control group was unchallenged. The two groups were matched in such a manner that both mean and 
standard deviation in sucrose consumption were similar. The animals were then placed in separate rooms. One 
group was exposed to an initial four week period of chronic mild stressors, while the other group was left undis-
turbed. Food and water was freely available for the unchallenged group, except 14 h before the sucrose consump-
tion test where the animals were food and water deprived. The stress paradigm persisting in four weeks involved 
one period of intermittent illumination, stroboscopic light, grouping of the animals, and food and water depri-
vation. Moreover, there were two periods with no stress and soiled cage and three periods of tilting the cage 45°. 
Stressors were exchanged every morning and night.
Sucrose consumption test. In order to quantify the hedonic state of the animals a sucrose consumption 
test was performed. The animals were trained in five weeks in order to consume a palatable sucrose solution. In 
the period of the five weeks training, the animals were tested twice a week during the first three weeks and only 
once a week the last two weeks. The animals were deprived for food and water in 14 h before the sucrose consump-
tion test. The test involved 1 h access to a 1.5% sucrose solution in a one bottle paradigm. When the stress period 
was initiated the sucrose consumption test was performed once a week. A cut-off of 20% increase in sucrose 
intake, compared to baseline, at the respective week was applied to define responders versus non-responders. 
To ensure that basic thirst was similar for all groups diurnal water intake was measured in the beginning of each 
week.
Drug administration. After four weeks of CMS exposure, the animals were treated with either drug or vehi-
cle for five weeks while still exposed to stressors. Etomoxir (Meta-IQ ApS, Denmark), a specific CPT1 inhibitor56, 
was heated to 37 °C and dissolved in sunflower oil. Etomoxir was administered intraperitoneally every day in a 
dosage of 4 mg/kg. Escitalopram (Lundbeck, Denmark) was dissolved in saline and was administered intraperito-
neally daily in a dosage of 5 mg/kg. The vehicle group received daily injections with sun flower oil intraperitone-
ally. All injections were administered in the morning and on Fridays subsequent to the sucrose test.
Intracellular staining for flow cytometry. Experiments involving human blood samples were carried out 
in accordance with the approved guidelines and regulations according to the Declaration of Helsinki. Informed 
consent forms of these donors have been obtained. The study and use of human blood material was approved by 
Ethical Committee for Region North Denmark (N-20150073). Blood lymphocytes were isolated from humans 
using a buffy coat. Sodium heparin full blood was centrifuged at 2000 g for 15 min and the white blood cell 
layer was harvested. To ensure harvesting of all white blood cells, the cells were centrifuged over a Ficoll density 
gradient at 2000 g for 10 min. The white blood cells were then harvested, centrifuged at 2000 g for 5 min and the 
supernatant was discarded. The cells were plated with a density of 2 × 106 cells/well in 6-well plates and grown for 
48 h. The cells were cultured in RPMI medium (cat#61870-010, Gibco, CA, US) containing 10% fetal calf serum 
(cat#10270-106, Invitrogen, CA, US) and 1% penicillin/streptomycin (cat#15140-122, Life Technologies, CA, 
US) in the presence or absence of staphylococcal enterotoxin B (30 ng/ml) (cat#S4881, Sigma Aldrich, MO, US). 
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Some cells were treated with Na-Etomoxir (100 μM) (cat#E1905, Sigma Aldrich, MO, US). After 48 h, the cells 
were re-suspended in phosphate buffer saline (PBS)/bovine serum albumin (BSA) (cat#EQBAH62-00, Europa 
Bi-products, UK), collected in tubes and centrifuged at 1500 g for 4 min. The supernatant was discarded and PBS/
BSA was added. The cells were plated into a 96-well plate, centrifuged at 1500 g for 4 min and the supernatant was 
aspirated. The cells were stained for APC mouse anti-human CD3 (cat#561810, BD Biosciences Pharmingen, CA, 
US) or PerCP-Cy mouse anti-human CD4 (cat#560650, BD Biosciences Pharmingen, CA, US) diluted in PBS/
BSA and incubated on ice for 1 h. The staining procedure was carried out according to Intracellular Staining Kit 
(cat#ANN0001, Intracellular Staining Kit, Invitrogen, CA, US). The cells were washed in PBS containing 0.5% 
BSA and centrifuged at 1500 g for 4 min twice, after which the cells were fixed in IC fixation buffer (cat#FB001C, 
BD Biosciences Pharmingen, CA, US) at 4 °C for 10 min. After washing two times in IC permeabilization buffer 
(cat#PB001C, BD Biosciences Pharmingen, CA, US), the cells were centrifuged at 1500 g for 4 min and the super-
natant aspirated. The antibodies FITC mouse anti-human IFN-γ (cat#561057, BD Biosciences Pharmingen, CA, 
US), PE mouse anti-human IL-4 (cat#562046, BD Biosciences Pharmingen, CA, US), mouse anti-human IL-8 
(cat#340509,BD Biosciences, Becton Dickinson Company, CA, US), PE mouse anti-human IL-17α (cat#560438, 
BD Biosciences Pharmingen, CA, US) and FITC mouse anti-human TNF-α (cat#562082, BD Biosciences 
Pharmingen, CA, US) diluted in permeabilization buffer were added and incubated on ice for 30 min. The cells 
were washed twice in permeabilization buffer and centrifuged at 1500 g for 4 min and lastly re-suspended in PBS 
for further analysis using flow cytometry.
Statistical analysis. All data are presented as mean ± SEM. P values less than 0.05 were considered signifi-
cant. The sucrose data were analysed by using repeated measures two-way ANOVA and one-way ANOVA with a 
Tukey multiple comparisons post hoc test. Differences in number of animals responding to treatment were ana-
lysed by Fishers exact test. The data concerning human peripheral blood lymphocytes were analysed by a two-way 
ANOVA with a Tukey multiple comparisons post hoc test.
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